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 Intramembrane proteases (IPs) play important roles in numerous biochemical 
processes in all kingdoms of life, including cell differentiation, development and 
metabolism.  IPs are attractive targets for therapeutics development and have been 
implicated in the pathogenesis of human diseases, such as Alzheimer’s disease, Hepatitis 
C, malaria and a variety of cancers. Despite their broad medical and biological relevance, 
structural and mechanistic details of IPs have remained largely obscure.  
 Intramembrane aspartyl proteases (IAP) are one of the four classes of IPs, and the 
least understood. Typically, discontinuous assays are used to study the biochemistry of 
IAPs. A major disadvantage of discontinuous assays is that the catalytic parameters, 
substrate preferences and modes of inhibition are difficult to extract with high degree of 
sensitivity and certainty. Therefore, in Chapter 2, I developed a continuous FRET peptide 
assay. The assay is fast, robust, and high throughput, and can be applied to screen 
multiple conditions simultaneously. In collaboration with the Torres Lab (School of 
Biological Sciences), we developed a liquid chromatography tandem mass spectrometry 
method (LC-MS/MS) to detect the cleavage sites with high-resolution. Catalytic 
parameters and cleavage sites of a fortuitous substrate, angiotensinogen, in detergent and 
bicelles condition were evaluated. In addition, the modes of inhibition of well-established 
IAP-directed inhibitors were identified.  
 Chapter 3 applies the methodology of Chapter 2 for structure-function analysis of 
a model IAP from the archaeon Methanoculleus marisnigri JR1 (mIAP). IPs are 
notorious as promiscuous enzymes where there is no consensus on substrate cleavage 
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motif; yet, IPs are believed to be highly regulated so as to not accidentally deactivate 
proteomes. The catalytic effects of mutations on conserved catalytic and gating motifs, 
and familial Alzheimer’s disease mutations on mIAP proteolysis were evaluated to shed 
light on the proteolytic mechanism, substrate recognition and gating. Utilizing LC-
MS/MS, the cleavage profiles of substrate obtained after mutant mIAP cleavage were 
compared to understand how mIAP mutations affect processivity and specificity of 
cleavage. To probe factors influencing substrate specificity of mIAP, such as chemical 
preference towards particular amino acid residue and positional preference on a particular 
substrate sequence, a series of substrates, including mutants of the angiotensinogen 
sequence as well as the C-terminal region of amyloid precursor protein involved in 
Alzheimer disease, were generated and cleavage reactions with mIAP were evaluated.  
 Finally, in Chapter 4, I present a small-angle neutron scattering (SANS) study of 
mIAP. The oligomeric state of IAPs has been a subject of debate, with proposals from 
monomer through octamer. The presence of detergent or other amphiphilic systems 
required to solubilize and stabilize membrane proteins hinders structural characterization 
using standard analytical techniques such as size exclusion chromatography (SEC) 
coupled with multi-angle light scattering (MALS), or small-angle X-ray scattering 
(SAXS). SANS offers a unique feature that can highlight membrane protein rendering 
detergent micelles invisible by matching the scattering length density of solvent with that 
of detergent. This study was done in collaboration with the Biological Neutron Scattering 





1 Chapter 1: Introduction to intramembrane proteases (IP) 
 
 
1.1 Biology of intramembrane proteases (IP) 
Intramembrane proteolysis is a biochemical process in which a membrane-
embedded substrate is hydrolyzed within the transmembrane (TM) helix by an 
intramembrane protease (IPs) to release a biologically active peptide/protein that in turn 
translocates to different regions of the cell to elicit a biological function (1). 
Intramembrane proteolysis plays an important role in cell metabolism, development and 
differentiation in organisms throughout the kingdoms of life (2). Eukaryotic IPs are 
composed of several membrane-spanning helices embedded in the membrane of 
endoplasmic reticulum (ER), Golgi, cell membrane. IPs are essential in cell signaling 
cascade that control metabolism, and control activation of transcription factors that then 
influence expression of different genes (1-4). Dysfunction of IPs lead to a multitude of 
diseases (5-7). As such, IP inhibition is a broad strategy in related drug development 
(8,9). Despite their biomedical importance, little is known about the mechanism and 
substrate specificity of IPs.  
1.1.1 Basic features of the four classes of IPs 
IPs are divided into four distinct classes based on their key catalytic nucleophile: 
(1) serine proteases called rhomboids, (2) Zn-dependent metalloproteases or site-2-
proteases (S2P) (3) glutamate proteases and (4) aspartyl proteases (IAPs). IPs are found 
in all kingdoms of life except glutamate protease which is only found in eukaryotes (10-
13). In Drosophila melanogaster, rhomboid is the primary regulator of epidermal growth 
factor receptor (EGFR) signaling pathway controlling the organismal development (14).  
2 
 
Mutations in rhomboid are found to be associated with developmental defects in 
Drosophila embryo (15,16). In addition, rhomboids play essential roles in other signaling 
pathways found in invasion of parasites (17) and quorum sensing of bacteria (18,19). In 
humans, rhomboid dysfunction has been linked to several diseases including Parkinson’s 
disease, malaria infection and colorectal cancer (17,20-23).   
Out of the four classes of IP, rhomboids are the best studied with several crystal 
structures available from various organisms. Rhomboids utilize a catalytic dyad 
containing Ser and His during proteolysis rather than utilizing a classical Asp-Ser-His 
catalytic triad of soluble serine proteases (24,25). The catalytic residues are buried at the 
bottom of a V-shaped cavity, about 10-12 Å away from the membrane surface (26). 
Catalytic Ser and His are located on TM4 and TM6 respectively (Figure 1.1A). Histidine 
is thought to activate Ser for direct nucleophilic attack on the substrate during proteolysis 
(27).  Two models were initially proposed for substrate gating in which substrate is 
thought to enter active site via a lateral gate, which could be formed by amphiphilic loop 
1 (L1) (28) or TM5 (26,29,30). The amphiphilic characteristic of L1 forms a lid between 
the active site and lipid, so movement of L1 could open up the path between TM1 and 
TM3 for substrate entry into the active site (28). Alternatively, and more convincingly, 
substrate could enter via lateral gate involving TM5 (29,30) (Figure 1.1A). Outward 
bending of TM5 is thought to create a lateral opening where substrate could enter the 








Figure 1.1. Structures of intramembrane proteases. (A) Rhomboid protease containing six 
TM helices, loop 1 (L1) and catalytic dyad Ser-His. (B) Site-2-protease containing six 
TM helices, zinc molecule (shown by gray sphere) coordinated to two His and an Asp 
residue, and Glu that is the activator of water for nucleophilic attack on scissile bond. (C) 
Glutamate protease, RceI, containing eight TM helices, catalytic Glu and His and 
peripheral helices αA and αB. (D) Aspartyl protease, presenilin homolog, containing nine 






Kinetic studies on rhomboid have raise a controversy about intramembrane 
proteolysis process. One study, using a biological substrate peptide consisting of a lipid-
quenched fluorescein isothiocyanate (FITC) fluorophore, provocatively argued that 
intramembrane proteolysis by rhomboid is governed by turnover number (kcat), not by 
substrate affinity (31). Screening structural variants of biological substrate yielded a weak 
affinity in high micromolar range for all substrate variants but a significant difference in 
kcat among substrate variants tested. On the contrary, two other studies, utilizing a 
fluorescent casein or fusion substrate containing a cyan and yellow fluorescence proteins 
as a FRET pair, suggest a more conventional scenario in which substrate affinity plays an 
important role in intramembrane proteolysis (10,32).  
In two studies with rhomboids, a specific sequence recognition motif has been 
identified (33,34). Seven residues on either side of the cleavage site were examined via 
mutagenesis to understand the substrate protein primary structural determinant on the 
substrate specificity of rhomboids. Three residues positions, P4 (fourth residue N-
terminal to the cut site), P1 (first residue N-terminal to the cut-site) and P2’ (second 
residue C-terminal to the cut site), were identified to be crucial in specificity, rate and 
efficiency of cleavage (33). While P4 position requires large and hydrophobic residues, 
P1 position prefers amino acids with small side chain and P2’ position favors 
hydrophobic side chains regardless of their size. The aforementioned requirements at P4, 
P1 and P2’ extend to diverse substrate proteins from prokaryotes and eukaryotes 




S2P is a zinc-dependent metalloprotease mainly involved in cholesterol 
metabolism (35). In response to low level of cellular cholesterol, membrane-bound 
transcription factor called sterol regulatory element-binding protein (SREBP) is 
translocated from the ER to the Golgi apparatus, where it is sequentially cleaved by site-
1-protease (S1P) and S2P (36,37). In the Golgi, S1P cleaves SREBP at its lumenal loop, 
thus separating two transmembrane segments. S2P then cleaves the first transmembrane 
segment within lipid bilayer to release a mature amino-terminal (N-terminal) portion of 
SREBP, which in turn enters nucleus to activate transcription of genes that control 
biosynthesis and uptake of cholesterol (38,39).  
S2P consists of six transmembrane helices (TM1 – TM6) (40). TM helices 2,3 
and 4 together form the core domain of S2P, which has conserved amino acid sequence 
and conserved active site conformation across various species. In the core domain of S2P, 
TM 2 and 4 are stabilized by TM3. The active-site contains the catalytic zinc atom 
coordinated by two histidines in TM2 and one aspartate in TM4 (Figure 1.1B) (40). The 
zinc atom is ~14 Å from the membrane surface. S2P is crystalized in a closed and open 
conformation. Compared to the closed state, TM1 and TM6 are 10-12 Å farther apart in 
the open conformation. In the closed state, the active site is embedded in the 
transmembrane helices and is impermeable to the substrate peptide. However, water 
molecules, which are key for hydrolysis, can travel to the zinc ion in the active site via a 
polar, central channel that opens to the cytosolic side of the cell membrane. A glutamate 
residue is thought to activate the water molecule to initiate nucleophilic attack on 
substrate. The open conformation exposes the active site to the substrate entry via the 
deep groove that run roughly parallel to the TM segments. The conformational change 
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from closed to open state is thought to occur through the lateral gating mechanism in 
which two sides of the gates (ie. TM1 and TM6) move away from each other. It is still 
not clear if the substrate enters the active site between TM1 and TM2 or between TM6 
and the core domain.  
 The glutamyl zinc-containing intramembrane protease, RceI (Ras and α-factor 
converting enzyme I) is a more recent addition to IPs because it utilizes catalytic 
glutamate residue that is distinct from three other classes of IPs  (41). In addition, RceI 
has no sequence similarity to other IPs and strong evidence indicates that RceI is not a 
metalloenzyme because it can function without zinc (41,42). RceI was first identified in 
Saccharomyces cerevisiae as a type II CAAX prenyl endopeptidase (where C is cysteine, 
A is an aliphatic amino acid and X is any amino acid) (12,43). RceI is involved in the 
three-step posttranslational modification of CAAX proteins which affect multiple 
signaling pathways that control differentiation, proliferation and oncogenesis (44,45). 
First, a CAAX protein is prenylated with a help of prenyl-transferase, which attaches 15-
carbon farnesyl or 20-carbon geranylgeranyl moiety to the cysteine of CAAX motif at the 
carboxy terminal (C-terminal). The prenylated CAAX protein is then cleaved by RceI 
releasing the last three amino acids (-AAX) and exposing isoprenyl cysteine which is 
further modified via methyl esterification. The cleavage of CAAX protein by RceI is 
required for proper localization (46). Germline knockout of RceI results in embryonic 
lethality in mice suggesting the importance of RceI in organismal development (47,48).  
The RceI is composed of eight transmembrane helices (TM1-8) and two 
peripheral helices (αA and αB), which make it topologically distinct from other IPs 
(Figure 1.1C). Four transmembrane helices (TM4-7) are surrounded by less conserved 
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TM1-3 and TM8. A large conical cavity contains catalytic dyad, Glu and His, at the top 
of the cavity which open wide to the cytoplasm allowing unrestricted solvent access to 
the active site (41). Catalytic Glu, whose pKa is potentially raised by contacting two 
conserved Trp residues, is thought to deprotonate water for nucleophilic attack on the 
scissile bond. The oxyanion transition state is proposed to be stabilized by His and Asn, 
which are positioned on successive helical turns of TM7 opposite to the catalytic dyad. 
Protonation of the leaving amino group on the AAX tripeptide could perhaps be 
catalyzed by either residue of catalytic dyad, Glu or His. Substrate is proposed to enter 
active site laterally between TM2 and TM4. A large volume catalytic conical cavity is 
thought to accommodate various sizes of prenylated substrate proteins.  
IAPs, the fourth class of IPs and the IP characterized in this thesis, is involved in 
various cellular processes such as cell differentiation, development, immune surveillance 
and viral maturation (2). IAP utilizes membrane-embedded two aspartic residues, which 
are located on two adjacent TM helices, during catalysis. Presenilin and signal peptide 
peptidase (SPP) are key members of IAP family. Although presenilins were once thought 
to be only found in vertebrates, bioinformatics analysis suggest that the presenilin-like 










Figure 1.2. PROMALS 3D sequence alignment of human presenilin-1 (accession 
P49768, PDB code 5FN5) and archael IAP (accession ABN57850, PDB code 4HYC). 
Alignment conducted in PROMALS3D (49). 
 
Both presenilin and SPP are composed of 6-9 TM helices (Figure 1.1D). Despite 
their low sequence identity of 19%, presenilin and SPP share catalytic motifs, YD 
(TM6)…GxGD (TM7) (where Y is tyrosine, G is glycine, D is aspartate and x is any 
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amino acid) (50-55); similarities extend to microbial orthologs (Figure 1.2)  (51-53,56). 
However, the roles of ‘Y’ and ‘G’ in the signature motifs are not clear. Presenilin and 
SPP are inhibited by the same transition state analog (50-53) suggesting a conserved 
active site. Structural comparison of presenilin and SPP shows a nearly perfect register of 
the catalytic aspartates and similar features at active site (57). However, presenilin and 
SPP have opposite membrane topology which could be related to the fact that presenilin 
cleaves type I membrane proteins (where carboxyl-terminal faces cytosol) whereas SPP 
cleaves type II membrane proteins (where amino-terminal faces cytosol) (58). Although 
presenilin requires the other subunits of the γ-secretase complex for optimal activity, SPP 
does not require any other component for its activity (58-60). Finally, it has been 
proposed that conserved motif, Pro-Ala-Leu (PAL) on TM9 in presenilin could be 
involved in substrate recognition and gating (61-63).  
1.2 Biology and biochemistry of IAPs 
1.2.1 Biological roles of presenilin 
A well-known involvement of presenilin is its role in cleaving substrates 
implicated in Alzheimer’s disease (Section 1.4) but presenilin has been found to carry out 
multiple functions beyond the catalytic role for γ-secretase. Presenilin has been identified 
to be involved in protein trafficking, calcium homeostasis, and cell signaling pathways 
(64). For example, it has been reported that presenilin mutations promote the release of 
Ca2+ from overloaded ER stores leading to the abnormal intracellular calcium signaling 
(65). Presenilin may also function as a low-conductance, passive ER Ca2+ leak channel 
(66). Finally, presenilin negatively regulates the level of β-catenin, which is a signal 
transducer protein as well as cell adhesion molecule, by physically interacting with β-
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catenin via the cytosolic loop of presenilin (67-71). In presenilin-deficient mice, the β-
catenin signaling is enhanced leading to the development of skin cancer (72).  
1.2.2 Biological roles of SPP  
SPP is found in bacteria, archaea and eukaryotes including fungi, protozoa, plants and 
animals highlighting its physiological importance (13,58). SPP cleaves the remnant signal 
peptides remaining in the ER membrane after cleavage by signal peptidase, a soluble 
enzyme (51,73). SPP initiates the immune response by cleaving the signal peptide of 
polymorphic major histocompatibility complex (MHC) class I molecule, which then 
generate human leukocyte antigen (HLA) epitope. (74). In addition, SPP is involved in 
maturation of pathogens such as Hepatitis C virus and malaria parasites (75-77). Loss-of-
function studies of SPP in various animal models demonstrate the essential role SPP 
plays in development. For example, antisense-mediated SPP knockdown in zebrafish 
resulted in developmental defects and neuronal cell death (78). Likewise, SPP deficient 
larvae of Drosophila have abnormal tracheae and died early (79). Exogenous addition of 
active SPP rescues normal development of Drosophila larvae, suggesting that the 
intramembrane proteolysis by SPP is crucial in larval development (79).  
1.2.3 IAP substrate requirements and specificity 
Currently, there are about 90 substrates identified for γ-secretase and 30 substrates 
for SPP, and no consensus motif for substrate cleavage has emerged (5,59). For both 
presenilin and SPP, most substrates are the products of another protease; β-secretase 
cleaves APP to provide C100 substrate for presenilin and signal peptidase cleaves its 
substrate to provide signal peptide for SPP (80-82). Although substrate transmembrane 
orientation and ectodomain length were initially thought to be required features for IAP 
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hydrolysis, substrates that fail to follow those two rules have been reported, suggesting 
that factors influencing substrate recognition are more complex (83). γ-secretase does not 
seem to recognize the scissile bond by TM depth as it is capable of cleaving at various 
sites throughout a given TM substrate (84-86) and comparative analysis of substrates 
reveals high variability in amino acid sequence and length (87,88).  It has also been 
suggested that helix-breaking residues within TM helix at or around the scissile bond are 
required for the cleavage. This feature is thought to destabilize the TM helix by 
unwinding it, thereby exposing the scissile bond to the protease (80,89,90). However, 
there are examples of canonically helical cleavage sites in the literature (51,52). In sum, it 
is still unclear how intramembrane proteases differentiate substrates from non-substrates.  
1.3 Challenges working with IPs 
Working with membrane proteins like IAPs in the laboratory is notoriously 
challenging. First, IAPs are not soluble in aqueous solution, so mild detergents or other 
chemicals that can mimic the physiological lipid bilayer are required in order to retain the 
enzyme in an active state in vitro. Determination of suitable detergent or lipid system, 
and concentrations of these reagents, varies on a case-by-case basis and is empirically 
evaluated. Low and high detergent concentrations can be detrimental to the enzyme, 
rendering the membrane protein insoluble and denatured. Detergents can also interfere 
with the downstream analysis tools such as mass spectrometry (MS), circular dichroism 
(CD), nuclear magnetic resonance (NMR) and ligand-binding studies (91). In the case of 
MS, the presence of detergent interferes with protein digestion by commonly used 
soluble proteases (92,93). The ability of resulting cleaved peptides to bind to the 
chromatography column is also influenced by detergent. The final peptide peak 
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intensities are often reduced because detergent interferes with analyte ion signals, 
interfering with detection (94-96). In the case of CD, the hydrophobic and anisotropic 
nature of detergent gives rise to spectral artifacts such as solvent-induced wavelength 
shifts, differential light scattering and absorption flattening (97). The dielectric constant 
(~ 1-2) of hydrophobic core of detergent is considerably lower than that of water (~80) 
causing bathochromic and hypsochromic shifts in CD spectrum of membrane proteins 
(98,99). Differential light scattering and absorption flattening, caused by detergent, 
influences the magnitudes and ratios of different peaks, thereby distorting the shape of 
the CD spectrum (100-102). In the case of NMR, membrane protein associated with 
detergent micelles tumbles as part of a larger complex leading to signal broadening, poor 
sensitivity and reduced spectral resolution (103).  
1.4 IP involvement in human diseases 
IPs are attractive targets for drug development due to their involvement in the 
pathogenesis of various human diseases. Mitochondrial rhomboid has been of interest in 
therapeutic development for type 2 diabetes and Parkinson’s disease (21). Functionally 
impaired rhomboid has been detected in patients with Parkinson’s disease raising the 
possibility of rhomboid inhibition as a viable strategy to increase mitophagy as a 
treatment for Parkinson’s disease (104). Recently, S2P has been proposed as a novel 
therapeutic target for castration-resistant prostate cancer (105). Nelfinavir, originally 
developed as an HIV protease inhibitor, inhibits S2P, leading to accumulation of 
SREBPs, which in turn increases apoptosis for castration-resistant prostate cancer (105). 
RceI is a drug target in anticancer therapy. Inhibition of RceI disrupts the 
posttranslational modification of its substrate Ras, a family of membrane-bound G 
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protein involved in mitogen-activated protein kinase signaling pathway, which is linked 
to tumor growth (106).  
Presenilin was first identified through genetic linkage studies of families with 
early onset familial Alzheimer’s disease (FAD) (107). Presenilin is the catalytic subunit 
of γ-secretase, which also contains nicastrin, anterior pharynx-defective 1 (Aph-1), 
presenilin enhancer 2 (PEN-2) (64). All four protein components, which exist at 1:1:1:1 
stoichiometry (108), are required for the optimal enzymatic activity (109,110). Nicastrin 
is a single span membrane protein with a large, heavily glycosylated extracellular domain 
and is thought to assist in substrate selection (111). Aph-1, which is composed of seven 
TM helices, promotes the assembly, stabilization and trafficking of γ-secretase complex 
(112). PEN-2, which is composed of two TM helices, triggers presenilin endoproteolysis 
into N- and C-terminal fragments that together are catalytically competent (113-115). 
Amyloid precursor protein (APP) is the key substrate of γ-secretase involving in the onset 
of Alzheimer’s disease. APP is initially cleaved by a soluble aspartyl protease, β-
secretase, to produce a membrane-bound carboxyl-terminal fragment commonly known 
as C100 or C99, which in turn is cleaved by γ-secretase sequentially to liberate various 
length of amyloid-β (Aβ) peptides. Data to date indicate that γ-secretase cleaves within 
C100 at two membrane-embedded sites, first within the so-called ε-site to generate 48- 
and 49-mer peptides (Aβ48 and Aβ49), then at the γ-site to release shorter fragments 
Aβ38, Aβ40 and Aβ42 (116). Among the cleavage products of γ-secretase, Aβ42 is 
particularly prone to aggregation and is a component of the amyloid-β plaques in the 
brain of Alzheimer patients (64).  
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In addition to its major role in Alzheimer’s disease, γ-secretase has been 
associated with various cancers including breast cancer, lung cancer, colorectal cancer 
and T-cell acute lymphoblastic leukemia due to its cleavage of Notch (117). To date, 
clinical trials of γ-secretase inhibitors (GSIs) as a therapeutic for Alzheimer’s disease, 
have failed due to their severe side effects that rise from simultaneous inhibition of APP 
and other γ-secretase substrates like Notch (118). In sum, it is essential to understand the 
physicochemical principles behind γ-secretase and other IAP function in order to better 
tackle the selective inhibition needed to develop a successful therapeutic for Alzheimer 
and other diseases. 
1.5 Thesis objectives 
1.5.1 Development of a FRET-based IAP enzyme assay 
Chemical details of intramembrane proteolysis remain elusive despite its 
prevalence throughout biology. Typically, enzyme assay on IPs are discontinuous in 
which chemical reactions are quenched at specific time intervals and visualized using 
Western blot or ELISA. Discontinuous assay comes with different disadvantages: 1. data 
collection and processing takes days; 2. it is impractical to test on a variety of substrates 
and identify mode of inhibition from several inhibitors at once. Hence, we developed a 
continuous FRET peptide assay for an intramembrane aspartyl protease (IAP) from 
Methanoculleus marisnigri JR1 (MCMJR1) to study enzyme kinetics. Continuous assays 
give us real time measurement of product formation in a fast, robust and high throughput 
manner. A former postdoctoral fellow in our lab screened several commercially available 
hydrophobic FRET peptides and found that the renin 390 FRET substrate was cleaved by 
our IAP. In collaboration with the Torres lab (School of Biological Sciences), we used a 
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gel assay in combination with high resolution liquid chromatography (LC)-MS technique 
to identify the cleavage site of substrate. Catalytic rates and cleavage sites were 
determined in detergent and bicelles, a bilayer that resembles the lipid membrane. The 
modes of inhibition by three well-established IAP inhibitors and the role of the first TM 
helix in catalysis, were directly investigated.  
1.5.2 Structure-function and substrate specificity of IAP 
Mechanistic and biochemical details of intramembrane proteolysis accomplished by 
the aspartyl sub-class of intramembrane proteases, which is central to a number of 
biological processes, remain largely obscure. In this study, we explored how structural 
mutations of IAP affect its catalytic activity and cleavage profile using our continuous 
FRET assay coupled to LC-MS analysis (Section 1.5.1). The influence of catalytic motifs 
YD…GxGD and conserved PAL motif on proteolysis were evaluated. Next, we 
expanded our study to the C100 substrate of presenilin. In vitro kinetic parameters and 
cleavage sites of IAP toward the fortuitous renin substrate and C100 were compared, 
revealing a preference for threonine (Thr). Thr-scanning mutagenesis of the renin 
substrate were used to tease out physicochemical factors influence the IAP substrate 
specificity. Cumulatively, our study indicates that both chemical and positional 
preferences exist for IAP cleavage of respective substrate. 
1.5.3 Solution structure of IAP using small-angle neutron scattering 
(SANS) 
Despite their broad biomedical reach, basic structure-function relationships of IAPs 
remain active areas of research. Characterization of membrane-bound proteins is 
notoriously challenging due to their inherently hydrophobic character. For IAPs, 
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oligomerization state in solution is one outstanding question, with previous proposals for 
monomer, dimer, tetramer, and octamer. We used small angle neutron scattering (SANS) 
to characterize the solution structure of IAP. A unique feature of SANS is the ability to 
modulate the solvent composition to mask all but the enzyme of interest. The signal from 
the IAP can be enhanced by deuteration, and, uniquely, scattering from detergent and 
buffers were matched by the use of both tail-deuterated detergent and D2O. Results of our 
study indicate the our IAP is a compact monomer in solution, not higher ordered states as 



















2 Chapter 2: Catalytic properties of intramembrane aspartyl protease substrate 
hydrolysis evaluated using a FRET peptide cleavage assay 
 
2.1 Publication and author contributions 
The data presented in Chapter 2 has been published in ACS Chemical Biology with 
a citation: Naing, S. H., Vukoti, K. M., Drury, J. E., Johnson, J. L., Kalyoncu, S., Hill, S. 
E., Torres, M. P., and Lieberman, R. L. (2015) Catalytic Properties of Intramembrane 
Aspartyl Protease Substrate Hydrolysis Evaluated Using a FRET Peptide Cleavage 
Assay. ACS chemical biology 10, 2166-2174. The molecular cloning, site-directed 
mutagenesis, membrane protein expression and purification protocol were developed by 
Swe Htet Naing, Jason Drury, Sibel Kalyoncu and Jennifer Johnson under the guidance 
of Dr. Raquel Lieberman. The FRET peptide cleavage assay and gel-based assay were 
developed and performed by Swe Htet Naing. The expression and purification of 
substrate protein and fluorescence polarization study was carried out by Swe Htet Naing. 
The mass spectrometric methodology development and analysis were carried out by 
Krishna Vukoti and Matthew Torres. Shannon Hill performed the circular dichroism 
experiment for substrate, MRS.  
2.2 Introduction 
In spite of their biological importance and implications in diseases, relatively few 
details are known about the biochemistry of IPs. Contrary to intuition and knowledge of 
soluble proteases (119,120), data to date suggest that the three canonical IP classes do not 
exhibit a sequence recognition motif within their TM substrate, and, while helix 
disfavored residues within the TM segment are thought to be important for cleavage 
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(80,90), examples to the contrary appear in the literature (51,52). Detailed biochemical 
investigations of intramembrane proteins are notoriously challenging due to the need for 
lipids or lipid-mimicking detergents, which are largely incompatible with downstream 
analytical methods such as mass spectrometry (MS) often used to rigorously confirm 
products. For IPs, high levels of purity are also necessary to remove contamination by 
low abundance but active cellular proteases. Standard in the IP field is the use of a 
discontinuous activity assay involving the incubation of enzymes with epitope tagged 
substrates followed by detection of cleavage products by Western blot, ELISA, or Matrix 
Assisted Laser Desorption Ionization (MALDI) MS analysis. Such assays have been used 
extensively to clarify biological processes (reviewed in (121)), optimize purification 
protocols for the presence of lipid and/or detergent (122,123), and, especially for γ-
secretase, develop transition-state and non-transition-state γ-secretase inhibitors with 
therapeutic potential to selectively treat Alzheimer disease without affecting Notch (124).  
A recognized disadvantage of discontinuous assays is that catalytic parameters, 
substrate preferences, and modes of inhibition are difficult to extract with high degree of 
certainty, details that would be readily measured using a continuous assay. To the best of 
our knowledge, continuous assays to date have only been employed in the case of 
rhomboid, the most biochemically tractable IP. One provocative study proposes that 
catalysis is governed by the turnover number (kcat) and not substrate affinity, based on 
measurements with a biological peptide substrate containing a lipid-quenched fluorescein 
isothiocyanate (FITC) fluorophore (31). However, two other studies, one utilizing 
fluorescent casein and another involving a fusion protein containing Förster Resonance 
Energy Transfer (FRET) pairs cyan and yellow fluorescent proteins, present more a 
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conventional scenario for an enzyme, with measured Michaelis constant (Km) and 
maximal velocity (Vmax) values in the low micromolar and mid nanomolar per minute 
range, respectively (10,32). The aforementioned studies and a related study on γ-secretase 
that used intensities from ELISA measurements in the discontinuous assay to extract 
catalytic parameters(125) converge on slow catalytic rates, but not substrate affinities or 
effect of detergent/lipid on reaction rates for IPs. Moreover, in the aforementioned 
studies, cleavage site(s) were not thoroughly investigated. Conversely, in a recent study 
of the purified and structurally characterized (54) intramembrane aspartyl protease (IAP) 
from Methanoculleus marisnigri JR1 (MCMJR1) in which resulting peptides were 
identified by MS, kinetics were not investigated (53). These examples motivate the study 
of IP enzymology to compare biochemical features among IP classes and resolve 
apparent disparities, as well as demonstrate the need to develop standard continuous 
assays coupled to high resolution analytical techniques to better comprehend biological 
intramembrane peptide processing. 
Here in Chapter 2, we present and implement a sensitive and rapid FRET peptide 
cleavage assay (Figure 2.1) to study the kinetic properties of purified MCMJR1 IAP, for 
which a structure is known but not biological function or substrate(s). The effects of 
detergent/lipid environment, the role of first N-terminal helix in activity, and mode of 
inhibition for three IAP- and γ-secretase-specific inhibitors (Figure 2.1), were examined. 
Results are compared to the typical gel-based discontinuous assay and cleavage sites are 
identified using quantitative proteomics MS analysis. Taken together, our study offers 
biochemical details of IAP and their inhibitors; demonstrates previously unappreciated 
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similarities with soluble aspartyl proteases; and provides new tools to study other IP 
family members in molecular detail.  
 
Figure 2.1. Illustration of FRET assay, chemical structures of fluorophores, quenchers, 
inhibitors and bicelle. (A) Pictorial demonstration of FRET assay. The release of 
fluorescence from EDANS is seen after cleavage by protease. (B) Chemical structures of 
fluorophores-quencher pairs (EDANS-DABCYL and NMA-DNP). (C) SPP-specific 
inhibitor (ZLL)2ketone and specific inhibitor of γ-secretase, DAPM and DAPT. (D) 





2.3.1 Cloning, expression, and purification of MCMJR1 IAP variants 
The full length IAP plasmid was generated by restriction free (RF) cloning (126). 
The target gene sequence was first amplified from genomic DNA of MCMJR1 (ATCC 
35101D-5) using specifically designed primers harboring 5’ NcoI and 3’ SalI restriction 
sites for ligation into pET-22b(+) vector (Table 2.1) and methods described in the RF 
cloning website (http://www.rf-cloning.org). The demethylated plasmid mixture was 
transformed into E. coli XL-10 Gold (Agilent), single colonies selected for overnight 
growth in Luria broth (LB media, Fisher) supplemented with 60 µg/mL ampicillin, and 
plasmid purified using QIAprep Spin Miniprep Kit (Qiagen). The sequence of IAPΔN23 
was amplified from genomic DNA using primers listed in Table 2.1 and ligated using 
traditional cloning procedures into the pET-22b(+) using restriction sites for NcoI and 
SalI. The two catalytic aspartates Asp 162 and Asp 220 were sequentially mutated to Ala 
in each IAP plasmid via site-directed mutagenesis (Agilent QuickChange II, Agilent) 























































For large scale expression of IAPs, plasmids of interest described above were 
transformed into E. coli Rosetta 2 cells (Novagen). Individual colonies were selected and 
grown overnight in 200 mL cultures of LB media supplemented with 34 µg/mL 
chloramphenicol and 60 µg/mL ampicillin at 37°C. Large cultures (1 L) were inoculated 
with overnight inoculum and grown in LB media supplemented with 34 µg/mL 
chloramphenicol and 60 µg/mL ampicillin in an orbital shaker (225 rpm, 37°C) until 
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OD600nm = 0.8-1 was reached. After chilling the cultures to 18°C for ~1.5 hr, protein 
expression was induced by the addition of 0.5 mM isopropyl-β-D-1-thigalactopyranoside 
(IPTG). Cultures were grown overnight and cells were harvested by centrifugation at 
5,000 x g, flashed cooled with liquid nitrogen for -80°C storage. 
To lyse cells, 8 g of cell paste was suspended in 35 mL of 50 mM Hepes (pH 7.5), 
200 mM NaCl containing Complete EDTA-free protease inhibitor cocktail (Roche). The 
cell suspension was lysed using a French press via 2 passages at 15,000 psi, and then 
centrifuged at 5,000 x g for 15 min for four times to remove cell debris. The supernatant 
was decanted and subjected to ultracentrifugation at 162,000 x g for 45 min. The pelleted 
membrane fraction was resuspended in the same buffer using a Dounce homogenizer, and 
the membrane fraction collected following repelleting by ultracentrifugation. For 
purification, ~0.3 g of membranes were first solubilized in 20 mL of 50 mM Hepes (pH 
7.5), 500 mM NaCl, 20 mM imidazole and 1% (w/v) DDM (1:10 DDM: cell mass, 
Anatrace) by gentle rocking for 1.5 hr at 4°C. Unsolubilized material was then isolated 
by ultracentrifugation at 162,000 x g for 45 min. The supernatant containing solubilized 
membranes was purified on a 1mL HisTrap FF Crude column (GE Healthcare) connected 
to an Akta FPLC or Purifier system. Purified enzyme was eluted by a linear gradient 
generated by mixing buffers containing 50 mM Hepes (pH 7.5), 500 mM NaCl, 20 mM 
imidazole, 0.1% DDM (buffer A) and 50 mM Hepes (pH 7.5), 500 mM NaCl, 500 mM 
imidazole, 0.1% DDM (buffer B). Elution fractions were pooled and buffer was 
exchanged to 20 mM Hepes (pH 7.5), 250 mM NaCl, 0.05% DDM (gel filtration buffer) 
in a 15 mL Amicon Ultra MWCO 50K concentrator (Millipore). The final sample (500-
900 µL) was further fractionated using a HiPrep 16/60 Sephacryl -S300 (GE Healthcare) 
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equilibrated with gel filtration buffer. Pure enzyme, which elutes from the column at a 
retention volume of ~60 mL, was exchanged to phosphate-buffered saline (PBS, 10 mM 
sodium phosphate, pH 7.2, 150 mM NaCl) supplemented with 0.05% DDM (pH 7.2) 
using the aforementioned concentration device. Protein purity was assessed by denaturing 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis (12% 
polyacrylamide) stained with Coommasie (127) (Figure 2.2) and concentration was 
measured using a NanoDrop spectrophotometer (ThermoScientific) (ε = 33,920 M-1 cm-1 
for IAP and ε= 27,300 M-1 cm-1 for IAPΔN23 calculated using the ExPASy ProtParam 
Tool (128) and molecular weights calculated from respective amino acid sequences for a 
monomer) at 280 nm. 
2.3.2 Standard assay and inhibitor studies  
The renin 390 FRET (Ren390FRET) substrate (R-E(EDANS)-IHPFHLVIHT-
K(DABCYL)-R, Anaspec) (where EDANS stands for 5-[(2-
aminoethyl)amino]naphthalene-1-sulfonic acid  and DABCYL stands for [4-((4-
(dimethylamino)phenyl)azo)benzoic acid] was dissolved in DMSO (500 µM stock 
concentration). Freshly purified IAP sample (0.5 µM) in 10mM sodium phosphate, pH 
7.2, 150 mM NaCl (PBS), 0.05% DDM or reconstituted into bicelles (see below), and 
Ren390FRET (3-40 µM) in PBS with 0.05 % DDM, were mixed by gentle pipetting in a 
96-well black-bottomed non-binding plate (Corning Inc.) and sealed with optical 
adhesive film (MicroAmp). The fluorescence values were monitored every 2 min over 
the course of an hour at 37°C in a Synergy 2 plate reader (BioTek, filters λex= 360 ± 40 
nm, λem= 485 ± 20 nm). A blank at each substrate concentration was prepared without 
IAP enzyme and data analyzed as described below. 
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The three inhibitors used in this study, 1,3-di-(N-Carboxybenzoyl-L-leucyl-L-
leucyl)aminoacetone ((ZLL)2ketone), N-[(3,5-Difluorophenyl)acetyl]-L-alanyl-2-
phenyl]glycine-1,1-dimethylethyl ester (DAPT) and N-[N-3,5-Difluorophenacetyl]-L-
alanyl-S-phenylglycine methyl ester (DAPM) were obtained from Calbiochem and 
prepared as 1 mM stock solutions in DMSO. The range of concentration of inhibitors 
used was 2x-60x molar excess over enzyme.  Freshly purified enzyme (0.5 µM) in the 
buffer listed above containing DDM was first incubated for an hour at 37°C with varying 
inhibitor concentration, then with Ren390FRET as described for the kinetics assay 
lacking inhibitors. Negative controls were prepared with all components except enzyme. 
Data were analyzed as described below. 
2.3.3 Data calibration and analysis.  
Fluorescence of free EDANS was plotted against concentration using the same 
settings as for the enzyme assay to convert from arbitrary fluorescence units (Afu) to 
concentration of hydrolyzed substrate. A correction factor (C) for the inner filter effect 
was established at each concentration of peptide used in the assay, as given by the 





where F(EDANS) is the fluorescence reading of free EDANS and F(EDANS+DABCYL) 
is the fluorescence reading of EDANS in the presence of equimolar amount of DABCYL. 
For each FRET peptide concentration used in experiments, C was applied to yield the 
corrected fluorescence value in nM/min.  
Data were well fit using the Michaelis-Menten analysis option within GraphPad 
Prism 5. Initial velocities were determined by the fluorescence reading over first 20 min, 
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subtracted from blank fluorescence, and then plotted against corresponding substrate 
concentrations. The Michaelis-Menten equation is V=Vmax[S]/( Km + [S]) where V is the 
initial velocity, Vmax is the maximum velocity at infinite substrate concentration, [S] is 
substrate concentration, and Km is the substrate concentration required to reach half the 
maximal velocity. Numerous independent samples of cell paste and purified enzyme were 
tested for each experiment; data and corresponding statistics presented include at least 20 
assay replicates for determination of kinetic parameters and 9 replicates for inhibitor 
studies. For each inhibitor, the mode of inhibition was determined by evaluating fits of 
different models, and Ki values were calculated from the competitive inhibition model 
within GraphPad Prism 5 using the equation 
𝑉 =  
𝑉𝑚𝑎𝑥 [𝑆]
𝐾𝑚 ( 1 +  
[𝐼]
𝐾𝑖
) +  [𝑆]
 
where Ki is the inhibition constant and [I] is the inhibitor concentration.  
2.3.4 Circular dichroism (CD). 
CD spectra and melts were conducted using a Jasco J-815 spectropolarimeter 
equipped with a Neslab RTE 111 circulating water bath and a Jasco PTC-4245/15 
temperature control system using a 0.1-cm pathlength cell. Ren390FRET without the 
fluorophore or quencher (IHPFHLVIHTR, Celtek) was dissolved in PBS with 0.05% 
DDM (0.2 mM peptide concentration) The spectrum was acquired from 300-195 nm at 
room temperature with a data pitch of 1 nm and a scan rate of 200 nm min-1. Duplicate 
samples of purified IAP and IAPΔN23 were prepared at 4 µM in same buffer at peptide 
concentration and spectra acquired from 300-200 nm at 4°C. The spectra presented are 
the average of 30 duplicate scans. Data were blank-subtracted and converted to molar 
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ellipticity Ɵ = (Ɵobs x 106)/(pathlength (mm) x c x n), where Ɵobs is the observed 
ellipticity (mdeg) at wavelength λ; c is the protein or peptide concentration (µM); and n is 
the number of residues. Enzyme thermal melts were performed in a 0.1-cm pathlength 
cell with 1°C min-1 increase in temperature from 4 to 80°C. Ten scans at 200 nm min-1 
from 300 to 200 nm were averaged at each temperature. Data at 222 nm were blank-
subtracted, converted to molar ellipticity, and plotted against temperature in GraphPad 
Prism 5. 
2.3.5 Fluorescence polarization (FP) 
Ren390FRET lacking the DABCYL quencher (Anaspec) was dissolved in DMSO 
at 500 µM. Different concentrations of IAP double mutant D162A/D220A, (0.6- 50 µM 
in PBS with 0.05% DDM), were titrated with renin 390 substrate (50 nM in PBS with 
0.05% DDM) for one minute and anisotropy readings were taken on an ISS 
spectrofluorometer (λex= 335 nm; λem = 495 nm) for ten iterations at 37°C. The data was 
analyzed with different models in GraphPad Prism 5 software, of which the best was one-
site total, which accounts for a specific binding site as well as a non-specific binding 
component. 
2.3.6 Bicelle preparation and reconstitution of IAP samples 
A 25% bicelle stock concentration was prepared as described previously (130). 
Briefly, dimyristoyl phosphatidylcholine (DMPC) and 3-([3-
cholamidopropyl]dimethylammonio)-2-hydroxy-1-propanesulfonate (CHAPSO) were 
added in molar ratio of 2.8:1 and dissolved in deionized water with 8-12 cycles of (1) 
heating at 42 °C for 10 min, (2) cooling on ice for 10 min, (3) vortexing and (4) freezing 
at -20°C for 10 min. The cold bicelle stock solution was added to the IAP enzyme sample 
28 
 
to obtain a final enzyme concentration of 0.5 µM for FRET-based assay and 16 µM for 
gel-based assay in 5% bicelle. The cold sample was mixed gently and then incubated on 
ice for an hour to complete the reconstitution process.  
2.3.7 Expression and purification of fusion protein substrate for gel 
assay 
DNA corresponding to fusion substrate MBP-IHPFHLVIHT-SUMO-6xHis 
cloned in pEX-K vector was purchased from MWG Operon. The plasmid was 
transformed into E. coli BL21 DE3 (Novagen) cells. A single colony was selected and 
grown overnight in 200 mL of LB media supplemented with 50 µg/mL kanamycin. Large 
scale cultures were grown in LB media containing 50 µg/mL kanamycin in an orbital 
shaker (225 rpm, 37°C) to an OD600nm = 0.6-0.8. Protein expression was induced with 0.5 
mM IPTG followed by growth for 3 hr at 37°C. Cells were harvested by centrifugation at 
5,000 x g, and flashed cooled with liquid nitrogen. For purification, 5 g of cells were first 
lysed by using a protocol analogous to that of enzymes above, except that the cell debris 
and membranes were removed in a single step by ultracentrifugation at 162,000 x g for 
45 min. The supernatant was loaded onto 1 mL HisTrap FF Crude column (GE 
Healthcare) and purified as above with buffers A and B, but omitting detergent. The 
elution fractions were pooled and buffer was exchanged to 10 mM Na2HPO4, 10 mM 
KH2PO4, 200 mM NaCl, 1 mM EDTA (Buffer A for MBPTrap HP Column purification) 
by four-fold concentration and dilution in a 15 mL Amicon Ultra MWCO 30K 
concentrator. The sample was further purified on a 5 mL MBPTrap HP column (GE 
Healthcare) connected to an AKTA FPLC or Purifier system equilibrated with buffer A. 
Purified substrate was eluted with buffer A supplemented with 10 mM maltose. Protein 
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purity (Figure 2.2) and concentration were evaluated as described above (calculated ε = 




Figure 2.2. Protein purification assessment by SDS-PAGE. (A) IAPΔN23 (B) single 
catalytic mutants of IAPΔN23 D162A, and D220A (C) IAPΔN23 double mutant (DM) 
(D162A/D220A) (D) IAP (E) single catalytic mutants of IAP D162A, and D220A (F) 
IAP DM. (G) MRS (MBP-IHPFHLVIHT-SUMO) substrate used for gel based assay. 
 
 
2.3.8 Gel-based enzyme assay with fusion substrate  
The fusion protein MRS substrate (4 µM) was incubated at 37°C with varying 
concentrations of freshly prepared enzyme sample in PBS, 0.05 % DDM or 5% bicelles 
and the reaction was stopped at varying time points by the addition of equal volume of 
Laemmli sample buffer containing β-mercaptoethanol, followed by storage at -20°C. The 
effect of enzyme concentration on cleavage was tested by incubating 4 µM fusion 
substrate with 1 µM - 48 µM of purified IAP or IAPΔN23 for 24 hrs at 37°C. For time 
course experiments, 4 µM substrate was incubated with 16 µM enzyme and samples were 
stopped at intervals between 2 hr – 48 hr.  
For inhibitor studies, (ZLL)2ketone, DAPT and DAPM (32 -320 µM) were added 
to 16 µM purified IAP or IAPΔN23 followed by the addition of 4 µM fusion substrate in 
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PBS, 0.05% DDM. The reaction was incubated at 37°C for 24 hours. Cleavage results 
were analyzed in two ways. First, 7 µL of quenched reaction samples were separated by 
SDS-PAGE (12% polyacrylamide) and visualized by Coomassie staining. Second, 2 µL 
of quenched reaction was subjected to SDS-PAGE followed by transfer to polyvinyl 
difluoride membrane (Biorad) and standard Western blot analysis using anti-MBP mouse 
monoclonal IgG primary antibody (Santa Cruz Biotechnology, 1:500 dilution), and horse 
radish peroxidase (HRP)-conjugated goat anti-mouse monoclonal IgG secondary 
antibody (KPL, 1:5000 dilution). Membranes were sprayed with HyGLO Quick Spray 
(Denville) and the images developed with autoradiography film.  
2.3.9 In-gel protein digestion and LC-MS/MS analysis 
 For analysis of cleavage sites, in-gel assays were conducted as described above, 
with the following modifications. At 4, 20, 24, and 48 hr, the reaction was stopped by the 
addition of ice-cold acetone (6.5 x sample volume) and samples were stored in -20°C 
until the completion of the experiment. Samples were centrifuged at 8,000 x g at 4°C for 
5 min followed by decanting the acetone and air-drying at room temperature for 30 min. 
Reducing Laemmli sample buffer was added to the precipitated materials which were 
then boiled in a 95°C bath for 15 min, pooled together and loaded onto a 12 % 
polyacrylamide gel for SDS-PAGE analysis and Coomassie staining.  
In-gel protein digestion was accomplished using a variation of the approach 
described previously (5). Unless otherwise noted, the various steps of the procedure were 
performed at room temperature and all incubation steps were performed under shaking 
(~750 rpm). Protein bands of interest in the Coomassie-stained SDS-PAGE gel were 
excised, cut into small pieces, transferred into a 1.5 mL microcentrifuge tube and washed 
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with 100 µL of deionized water. The supernatant was discarded and 100 µL of 
acetonitrile/50 mM ammonium bicarbonate (NH4HCO3; ABC) (1:1) was added to the gel 
pieces. This step was performed several times until the gel pieces were completely 
destained. After removal of the supernatant, the gel pieces were dehydrated with 100% 
acetonitrile followed by removal of the liquid by speedvac. After the gel pieces were 
completely dry, the proteins were reduced and alkylated with 10 mM DTT followed by 
55 mM iodoacetamide to eliminate disulfide bonding. The gel pieces were again 
dehydrated with acetonitrile and speedvac followed by rehydration with sequencing-
grade Glu-C (Promega) dissolved in 50 mM ABC until completely rehydrated. The 
excess liquid was removed and replaced with 50-100 µL of 50 mM ABC and incubated 
with shaking at 37 °C overnight. Acetonitrile was then added to 50% and shaken for 10 
min at room temperature followed by collection of the supernatant into a fresh 1.5 mL 
microcentrifuge tube. The gel pieces were incubated with 50% acetonitrile again as 
before and finally with 100% acetonitrile until the gel pieces were completely 
dehydrated. Supernatant was repeatedly collected in 1.5 mL tube, frozen and 
concentrated to dryness using a centrivap, and then resuspended in 5% acetonitrile/0.1% 
formic acid. In-gel digested peptides were analyzed by LC-MS/MS using a Nanoacquity 
UPLC (Waters) coupled with an LTQ Orbitrap XL mass spectrometer (Thermo) run in 
data-dependent mode (top-12). Resultant RAW files were analyzed by database matching 
using Proteome Discoverer (Thermo) and SEQUEST MS data interpretation algorithms 
trained on the protein of interest. Searching for unique cleavage sites was accomplished 
by setting the enzyme specificity to ‘none’, which facilitates a non-biased search for 
peptides generated through variable cleavage.  
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2.4 Results and Discussion 
2.4.1 Characterization of IAP and N-terminal deletion mutant 
IAPΔN23 
 IAP and a construct lacking the first 23 amino acids (IAPΔN23) were designed to 
examine the functional role of the first TM helix (TM1). This helix was previously 
believed to be structural (60,131) but the 3.3 Å resolution crystal structure of IAP, a 
tetramer in an inactive conformation, reveals the location of TM1 in the second shell of 
helices surrounding the apparent IAP active site, where it is not obviously involved in 
tetramer stabilization (54) (Figure 2.3A). TM1 abuts catalytic Asp220-containing TM7 
approximately at its midpoint. The N-terminus of TM1 and neighboring TM7 and TM8 
are rich in Leu and other hydrophobic residues (Figure 2.3A), raising the possibility that 
low energy alternative TM helical arrangements exist. We postulated that an IAP 
construct missing half of TM1 (IAPΔN23) would retain the overall quaternary structure, 
and insight into the role of TM1 could be gained. Specifically, if TM1 gates substrate 
access, the deletion construct would exhibit increased activity, a rationale used previously 
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for rhomboid (29), whereas if TM1 is needed to form a catalytically-competent active 
site, activity of IAPΔN23 would decrease.  
 
 
Figure 2.3. Initial characterization of IAP and IAPΔN23 constructs. (A) Structure of IAP 
(PDB code 4HYC) showing the nine transmembrane helices of one IAP monomer in the 
context of the crystallographic tetramer (grey except for red catalytic aspartates) in two 
orientations (left, center) and top-down zoom into the active site from top face depicting 
two catalytic aspartate residues and neighboring leucine residues (right). (B) CD spectra 
acquired at 4°C. (C) CD thermal melts over the range of 4–80°C, monitored at 222 nm. 
(D) Overlay of size exclusion chromatographs produced from HiPrep 16/60 Sephacryl-
S300. 
 
Both full-length IAP and IAPΔN23 were successfully purified to homogeneity 
(Figure 2.2). Their characterization by circular dichroism (CD) reveals, as expected, 
somewhat higher helical content in IAP than IAPΔN23 (Figure 2.3B). Thermal melts for 
both proteins are irreversible (not shown), but transitions related to the change in helical 
content are highly similar (Figure 2.3C). Finally, the main retention peak from size 
34 
 
exclusion chromatography remains unchanged between the IAP variants and IAPΔN23 
(Figure 2.3D). 
2.4.2 Development of a FRET-based assay 
After testing several commercially available fluorogenic substrates lacking 
charged residues renin 390 FRET (Ren390FRET) was identified. Ren390FRET contains 
the angiotensinogen sequence (IHPFHLVIHT) cleaved by the soluble aspartyl protease 
renin, flanked by EDANS fluorophore and DABCYL quencher. Incubation of freshly 
purified IAP with Ren390FRET resulted in enzyme concentration-dependent increases in 
fluorescence over time and thus Ren390FRET was used for the subsequent assay 
development and implementation. Assay parameters such as buffer, pH, plate type, plate 
seal, enzyme concentration, detergent identity and concentration, temperature, and 
duration were optimized for fluorescence signal. Characterization of the substrate lacking 
FRET pairs dissolved in the n-dodecyl-β-D-maltoside (DDM)-containing buffer used in 
the assay reveals no obvious secondary structure (Figure 2.4). 
 
 
Figure 2.4. Circular dichroism wavelength scan of substrate peptide (IHPFHLVIHTR) in 




Pseudo-first order, steady-state reaction conditions were implemented by using at 
minimum a five-fold molar excess of substrate over enzyme (132). Confirmation of this 
set up is supported by the similar values measured for the Km (Table 2.2) and dissociation 
constant Kd assessed by fluorescence polarization (FP) (Figure 2.5).  
 
Table 2.2. Kinetic parameters of IAP and IAPΔN23 using Ren390FRET substrate and 
inhibitors: (ZLL)2ketone, DAPT and DAPM, performed in DDM unless otherwise noted. 
  Enzyme  Inhibitor  Km  
(µM)  
Vmax  
(nM min–1)  
  kcat x 10
–3 
 (min–1) 
  (kcat / Km) x 10
–4 
  (µM–1 min–1) 
  IAP 
  IAPΔN23 
          - 5.2 ± 0.5 
8.3 ± 0.6 
2.25 ± 0.07 
1.12 ± 0.03 
  4.6 ± 0.3  
  2.2 ± 0.1  
  8.8 ± 1.3 
  2.7 ± 0.3 
  IAPa 
  IAPΔN23a 
          - 5.1 ± 0.6 
8.2 ± 0.6 
2.16 ± 0.09 
1.06 ± 0.03 
  4.3 ± 0.4 
  2.1 ± 0.1  
  8.4 ± 1.0 
  2.6 ± 0.3 
 
  IAP 
  IAP 
  IAP 
  IAPΔN23 
  IAPΔN23 









8.9 ± 0.6  
11.2 ± 0.8  
17.7 ± 2.1  
12.6 ± 0.9  
17.3 ± 1.0  
24.5 ± 2.0  
 
2.24 ± 0.06  
2.18 ± 0.06  
2.20 ± 0.10  
1.11 ± 0.04  
1.11 ± 0.04  
1.11 ± 0.05  
 
  4.5 ± 0.2 
  4.4 ± 0.2  
  4.4 ± 0.4  
  2.2 ± 0.2  
  2.2 ± 0.2  
  2.2 ± 0.2  
 
  5.1 ± 0.6 
  3.9 ± 0.5 
  2.5 ± 0.6 
  1.7 ± 0.4 
  1.3 ± 0.2 
  0.9 ± 0.2   
 
  IAP 
  IAP 
  IAP 
  IAPΔN23 
  IAPΔN23 









6.6 ± 0.5  
7.7 ± 0.6  
9.8 ± 0.9  
14.0 ± 1.0  
19.0 ± 2.0 
29.7 ± 3.0 
 
2.05 ± 0.05  
1.97 ± 0.05  
1.87 ± 0.07  
1.07 ± 0.04  
1.06 ± 0.06 
1.04± 0.07 
 
  4.1 ± 0.2  
  3.9 ± 0.2 
  3.7 ± 0.3  
  2.1 ± 0.2  
  2.1 ± 0.2  
  2.1 ± 0.3  
 
  6.2 ± 0.8 
  5.1 ± 0.7 
  3.8 ± 0.7 
  1.7 ± 0.3 
  1.1 ± 0.3 
  0.7 ± 0.9 
 
  IAP 
  IAP 
  IAP 
  IAPΔN23 
  IAPΔN23 









7.5 ± 0.6  
8.4 ± 0.7  
11.7 ± 1.0 
10.35 ± 0.8  
15.0 ± 1.0  
19.5± 2.0  
 
2.13 ± 0.07  
2.14 ± 0.07  
2.09 ± 0.09  
1.10 ± 0.04  
1.11 ± 0.04  
1.11 ± 0.05  
 
  4.3 ± 0.3  
  4.3 ± 0.3  
  4.2 ± 0.4 
  2.2 ± 0.2  
  2.2 ± 0.2  
  2.2 ± 0.2  
 
  5.7 ± 1.0 
  5.1 ± 0.9 
  3.6 ± 0.7 
  2.2 ± 0.3 
  1.5 ± 0.2 
  1.1 ± 0.3 




Binding of the substrate to the enzyme is best fit by a one-site binding model with 
Kd of 6.5 ± 2.0 M (Figure 2.5A). Thus, in our experiment, peptide cleavage events are 
the subsequent slow steps. Initial velocities were calculated as the slope of the increase in 
fluorescence over the first 20 min, after which a second slower rate was observed (Figure 
2.6). Data were converted to nM min–1 using the standard calibration curve for EDANS 
(Figure 2.7A), and a correction factor for the inner filter effect (Figure 2.7B) was applied. 
Lastly, DMSO is tolerated up to 4.2% (v/v) in the reaction mixture (Figure 2.7C), the 




Figure 2.5. Fluorescence polarization and enzymatic analysis for angiotensinogen 
substrate. (A) Fluorescence polarization using IAP double catalytic mutant 
D162A/D220A and Ren390FRET substrate lacking DABCYL. (B) Michaelis-Menten 
kinetics of Ren390FRET cleavage by IAP and IAPΔN23 in DDM and bicelles. (C), (D) 
Comparison of catalysis for wild-type IAP and IAPΔN23 along with single catalytic 





Figure 2.6. Assessment of initial catalytic rates for FRET assay. (A, B) Fluorescence 
readings for IAP at indicated concentrations over the course of 10 hrs. Initial velocity was 




Figure 2.7. Assay calibration. (A) Standard calibration curve of EDANS plotting the 
arbitrary fluorescence unit (Afu) against concentration of EDANS (nM). The 
fluorescence reading of free EDANS (5-100 nM) were taken under conditions used for 
FRET assay. (B) Inner filter effect (IFE) correction (C) Vehicle control test of DMSO on 




2.4.3 Kinetic analysis 
The reaction set-up in our FRET assay enabled direct determination of Michaelis 
Menten kinetics parameters, namely, Km and kcat, for cleavage of Ren390FRET by IAP 
and IAPΔN23 (Figure 2.5B). Catalysis was tested in detergent and after reconstitution 
into lipid bicelles, which are well-defined lipid bilayer discs with a central plane of 
phospholipid surrounded by amphiphile (130) that thus mimics the native lipidic milieu. 
Both enzymes are active, but IAP exhibits two-fold faster kinetics compared to 
IAPΔN23, in both in detergent and bicelles (Table 2.2). Alternative analysis of data by 
the Hill equation yielded poor fits (not shown); there is no evidence of the cooperativity 
observed in rhomboid (10) for IAP or IAPΔN23. As estimated by Km, affinity of 
Ren390FRET for IAPΔN23 is about 1.6 fold weaker than for IAP. The requirement for 
aspartates present in the signature motif YD and GXGD (where X is any amino acid) 
(133) was confirmed by single catalytic variants of IAP and IAPΔN23 harboring D162A, 
D220A, or the double mutant D162A/D220A; none exhibited enzyme activity (Figure 
2.5C,D). Thus, results from the FRET assay indicate that while both IAP and IAPΔN23 
are active, require the previously identified aspartates, but kinetics remain unchanged in 
bicelles and detergent.  
The low micromolar Km measured for the fortuitous Ren390FRET substrate is in 
the range for that reported for renin (1.8 µM) (134) and a renin-like fungal aspartic 
protease (4.3 µM) (135), as well as for purified, detergent-solubilized γ-secretase with the 
physiological and widely used C100-flag substrate, which contains a flag-tagged TM 
substrate and the C-terminal 100 residues of APP (0.28-1 µM) (125,136). Regarding 
other IPs, our Km is in line with reports for purified, detergent-solubilized E. coli 
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rhomboid GlpG using the non-biological and soluble fluorescent substrate casein (0.87 
µM) (32), purified P. stuartii rhomboid AarA paired with its substrate TatA (7.6 µM) 
(10), as well as Rce1 with its biological substrate K-ras (0.5 µM) (137); however, our 
value is notably lower than the ~135 µM value measured for rhomboids with a quenched 
peptide substrate (31). Our kcat values are detectable and similar to that reported recently 
for partially active γ-secretase with C100-flag (8 x 10-3 min–1) (125) but slower than 
purified rhomboid in detergent (0.8 min–1 (31), and 0.066-1.06 min–1, depending on 
rhomboid ortholog paired with the TatA substrate (10)). Slow catalytic rates measured in 
our assay may be explained in part by the fact that the angiotensinogen sequence is not 
the native substrate for our IAP, and likely could be increased if a biological substrate in 
the host organism MCMJR1 were identified. Nevertheless our results are consistent with 
the idea that in contrast to well-studied soluble proteases (119,120), proteolysis in the 
membrane is sluggish. 
2.4.4 Mode of inhibition of three small molecules  
Numerous inhibitor studies have compared inhibition profiles of γ-secretase and 
other IAPs (50,138-140), but details of pharmacological differences among compounds 
are active areas of investigation, typically relying on radio-(136), photoaffinity- 
(138,141) labeling methods. Here, the inhibitory effects of the SPP-specific inhibitor 
(ZLL)2ketone,  (50,136), and γ-secretase inhibitors, DAPT (142) and DAPM (143) on 
IAP and IAPΔN23 activity were examined in detergent; parallel experiments in bicelles 
were not possible due to the incompatibility of DMSO required to dissolve inhibitors 
with the low temperature incubation for IAP bicelle reconstitution. (ZLL)2ketone was 
most potent, displaying a reduction of activity with just 2x molar excess over the enzyme 
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(Figure 2.8A, B). Comparison of different inhibition models favors competitive inhibition 
for both IAP and IAPΔN23, consistent with the apparent increase in Km and unchanged 
Vmax with the increase in compound concentration (Table 2.2). The calculated Ki for 
(ZLL)2ketone toward IAP is 1.9 ± 0.2 μM. DAPT and DAPM are weaker inhibitors of 
IAP and IAPΔN23, as they require significantly higher concentrations to reduce enzyme 
activity (Figure 2.8C–F). Like (ZLL)2ketone, DAPT appears to be a weak competitive 
inhibitor of IAP, and inhibition is even less efficient toward IAPΔN23 (Table 2.2). 
DAPM is a very weak competitive inhibitor, increasing the apparent Km of both enzyme 
versions by just 2.3-fold even at the concentration of 60x, without appreciably altering 
Vmax. The corresponding Ki values for DAPT and DAPM for IAP are 16.9 ± 1.7 and 20.5 
± 2.2 μM, respectively. 
Although comparison of the substrate- and enzyme-concentration independent 
inhibitor constant (Ki) values for (ZLL)2ketone, DAPT, and DAPM from our continuous 
assay are not directly comparable to reported half-inhibitory concentration (IC50) values 
for different inhibitors toward SPP or γ-secretase, analysis of their modes and potency of 
inhibition is revealing. Early in vitro studies of SPP presumed that (ZLL)2ketone is an 
active site directed and a transition-state analog inhibitor (136) even though weakly 
electrophilic ketones are not used as inhibitors of soluble aspartyl proteases (144). Our 
assay demonstrates that (ZLL)2ketone is indeed a competitive inhibitor of IAP acting on 
Ren390FRET, but with a modest Ki. This result points to possible different mechanistic 
details between soluble and intramembrane classes of aspartyl proteases, perhaps due to 
the dearth of available water within the membrane. Conversely, for the two γ-secretase 
inhibitors, competitive inhibition ~10-fold weaker than (ZLL)2ketone was measured. To 
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date, multiple studies have been unable to measure appreciable inhibition of SPP by the 
γ-secretase inhibitor DAPT (50,145,146), which has been characterized as a non-
transition state analog that binds to an allosteric site on the C-terminal fragment of 
presenilin, with possible partial overlap with the active site (138,142). We anticipate that 
structure-activity-relationship inhibitor studies will be readily extended using our 
multiplexed continuous assay, or variations thereof using different substrates, to generate 
scaffolds with improved potency and selectivity for IAPs. 
 
 
Figure 2.8 . Inhibitor studies to determine mode of inhibition using Ren390FRET 
substrate. Kinetic data for (A) IAP treated with increasing (ZLL)2ketone, (B) IAPΔN23 
treated with increasing (ZLL)2ketone, (C) IAP treated with increasing DAPT, (D) 
IAPΔN23 treated with increasing DAPT, (E) IAP treated with increasing DAPM, and 
IAPΔN23 treated with increasing DAPM.  
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2.4.5 Gel-based assay. 
To independently verify cleavage and enable clear identification of cleavage site 
by MS, a discontinuous, gel-based proteolytic assay was employed. A fusion protein 
containing the angiotensinogen sequence flanked by an N-terminal maltose binding 
protein (MBP) and a C-terminal small ubiquitin-like modifier (SUMO) (MRS substrate) 
was designed to readily differentiate uncleaved substrate (~60 kDa) and the N- and C-
terminal products (~45 kDa and ~15 kDa). Western blot analysis clearly shows an 
increase in N-terminal product formation over the course of the reaction (2 h – 48 h) for 
IAP and IAPΔN23 in detergent and bicelles (Figure 2.9A, B), in an enzyme 
concentration-dependent manner (Figure 2.9C). Samples prepared without enzyme 
confirm that the substrate is not degraded over the course of the experiment. Similarly, 
catalytic aspartate-inactivated mutants do not form any cleavage products (Figure 2.9D, 
E). Reduced product formation was observed after incubation of either enzyme with 2x 
molar excess of (ZLL)2ketone and 10x of DAPT or DAPM (Figure 2.9F), and product 
formation was completely abrogated with 5x excess (ZLL)2ketone and 20x excess DAPT 





Figure 2.9. Gel cleavage assay using fusion protein substrate MBP-IHPFHLVIHT-
SUMO. (A) Time course in detergent. (B) Time course in bicelles. (C) Product formation 
as a function of enzyme concentration in detergent. (D,E) Activity of catalytic mutants, 
D162A, D220A and double mutant (DM) D162A/D220A. (F) Inhibition by 
(ZLL)2ketone, DAPT and DAPM. Negative control without enzyme (indicated by (-)) 
and positive control with renin are included. The uncut substrate and cleavage product 
(indicated by arrow in panel A) were detected by Western blot (see text).  
 
2.4.6 MS analysis.  
Although not all available TM sequences are expected to be substrates for IPs due 
to the need for tight regulation in the cell, cleavage of non-physiological substrates have 
been repeatedly demonstrated for S2P (90), IAPs (51-53), and rhomboid (10,31,32), and 
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there is a lengthy list of biological substrates documented for γ-secretase (147). Thus, 
even though signal sequences can be predicted by bioinformatics to ever-increasing 
degrees of certainty (148), details of recognition elements within IP substrates, 
particularly of the IAP class, remain obscure. Direct detection of cleavage products from 
our FRET assay proved unsuccessful likely due to the presence of a multitude of MS 
incompatible components within the reaction mixture. Thus, to determine cleavage-site 
specificity of IAP and IAPΔN23, we analyzed the 45 kDa MBP product from the gel-
based assay by in-gel digestion and LC-MS/MS. As a design feature of the MRS 
substrate, digestion with Glu-C protease produces a reporter peptide containing a single 
lysine residue, near the C-terminus of MBP but outside the angiotensinogen sequence, to 
enhance positive ionization of the peptide by nano-electrospray (Figure 2.10A). The 
average coverage of the MBP product band by LC-MS was between 87% – 93% and 
included the extreme N- and C-termini (across all experiments). Cleavage sites within the 
angiotensinogen sequence were detected by liquid chromatography (LC)-MS/MS of a 
product mixture after Glu-C digestion. Renin was used as a positive control to validate 
the cleavage assay with the MRS substrate. LC-MS/MS analysis of the resulting MR 




Figure 2.10. Mass spectrometric analysis of cleavage sites. (A) IAP and IAPΔN23 
primary cleavage site identified in this study. Peptides were generated by Glu-C digestion 
of the N-terminal product, facilitated by a C-terminal Glu within MBP (smaller triangle). 
(B) Peptide spectral matches (PSMs) of the reporter peptide relative to the PSMs for 5 
independent peptides from the N-terminal product after proteolytic cleavage in each 
condition. Bars represent the proportion of each cleavage reporter peptide (indicated by 
its C-terminal residue) relative to total PSMs across all detected version of the reporter 
peptide in each sample. Error bars represent the standard deviation among 3 LC-MS 
analyses from each sample. See also Figure 2.11, Figure 2.12 and Table 2.3 
 
Cleavage profiles of IAP and IAPΔN23 in both bicelles and detergent were 
examined next. To broadly survey cleavage with time and detect processivity, if present, 
each conditional reaction was stopped at four intervals (4, 20, 24, 48 hrs) and then 
combined into a single analysis. Thus, each MBP band contains a population of products 
resulting from cleavage at four different time points. In total, 24 independent LC-MS 
analyses were conducted across two biological replicates and each enzyme/detergent 
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combination. Three major observations were made based on the resulting data after 
quantitation of peptide spectral matches( Figure 2.10, Figure 2.11, Figure 2.12). First, 
cleavage by either IAP or IAPΔN23 was restricted to the reporter peptide and no other 
peptides were found that did not correspond to Glu-C peptides, confirming that, as 
expected, both IAP and IAPΔN23 cleavage were specific to the sequence between MBP 
and SUMO. Second, IAP and IAPΔN23 exhibited preferential cleavage between His and 
Thr within the renin substrate sequence and distinct from the renin cleavage site. To the 
best of our knowledge, the cleavage site His-Thr has only been reported once, for a 
secreted aspartic protease from C. albicans, coincidentally using the same 
angiotensinogen substrate (135). Cleavage was also found between T and M (the N-
terminal residue of SUMO) at approximately 50% abundance compared to H-T cleavage 
(Figure 2.10). Third, there was no significant difference observed in the cleavage site 
preference of IAP and IAPΔN23 in either bicelles or detergent, although the relative 
abundance of the H-T cleavage product was two times greater in bicelles versus 
detergent, suggesting that the reaction is more selective in bicelles (Table 2.3).  
Given the fact that the angiotensinogen sequence, while hydrophobic, is not a 
biological TM helix, nor does it exhibit obvious helical structure in solution (Figure 2.4), 
and in light of the promiscuity mentioned above for IPs, additional sites were anticipated. 
Only one other cleavage position, T-M, not present in Ren390FRET, was detected at 
appreciable levels. This site is similar to T-L reported as a primary cleavage position for 
IAP using a MBP-C100-His fusion protein (53); notably, we do not observe significant 
cleavage at L-V or V-I also reported in the same study. Thus, our findings raise new 
peculiarities regarding substrate recognition for IAPs and will enable systematic 
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investigations of sequence preferences at and beyond the scissile bond, as well as the 
extent of positional preferences or processivity, which are important aspects of γ-
secretase biology because such action leads to peptides of varying pathogenicity (150) 
but has only been explored to a limited extent in other IAPs (51,53).  
 
 
Figure 2.11. Mass spectrometric analysis (A) Representative SDS-PAGE analysis of N-
terminal product (MBP product, indicated by an arrow) produced by IAP and IAPΔN23 
in DDM and bicelle conditions. Positive control was prepared with renin and MRS. (B) 
Relative PSMs of cleavage products by renin from two biological replicates indicated as 








Figure 2.12. Relative PSMs of cleavage products formed by IAP and IAPΔN23 from two 
biological replicate indicated as experiment A and B. The LC-MS/MS analysis was 






















2.4.7 Structure-function analysis of TM1.  
The cumulative results of our assay indicate a role for TM1 in IAP catalysis. 
Direct comparison of activity was possible because the truncated IAPΔN23 construct 
remains stable and unchanged in oligomeric state compared to full length; such an 
experimental set up is expected to be difficult to probe other TM helices, such as TM6 or 
TM9 implicated previously in substrate binding (54,63). The lower Vmax, somewhat 
higher Km, more promiscuous cleavage, as well as weaker inhibition profile of IAPΔN23 
compared to full length IAP favors our proposed role for TM1 primarily in forming the 
native conformation of the active site over the possibility of substrate gating. For 
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example, TM1 could support TM7 in the proper position for Asp220, or provide 
physicochemical nuances relevant to proper substrate positioning within the active site. 
Taken together, our study reveals numerous heretofore unappreciated nuances of IAP 
family members. Our results and methodology set the stage for efficient in vitro 




















3 Chapter 3: Both positional and chemical variables control in vitro proteolytic 
cleavage of a presenilin ortholog 
 
3.1 Publication and author contributions 
The data presented in Chapter 3 has been published in Journal of Biological 
Chemistry with a citation: Naing, S. H., Kalyoncu, S., Smalley, D. M., Kim, H., Tao, X., 
George, J. B., Jonke, A. P., Oliver, R. C., Urban, V. S., Torres, M. P., and Lieberman, R. 
L. (2018) Both positional and chemical variables control in vitro proteolytic cleavage of a 
presenilin ortholog. The Journal of biological chemistry. The site-directed mutagenesis, 
FRET-based enzyme assays, CD thermal melts and protein expression/purification were 
carried out by Swe Htet Naing, Sibel Kalyoncu, Xingjian Tao and Josh George under the 
guidance of Dr. Raquel Lieberman. The gel-based assays and isotopic 18O labelling 
experiment were carried out by Swe Htet Naing, Xingjian Tao and Josh George. Mass 
spectrometric analysis was carried out by David Smalley, Hyojung Kim, Alex Jonke and 
Matthew Torres. Small angle X-ray scattering (SAXS) study and ab initio modelling 
were performed by Ryan Oliver and Volker Urban.  
3.2 Introduction 
Despite intense work in the area, how IPs distinguish substrates from non-
substrates and thus avoid deactivating a significant percentage of the proteome remains 
unclear (2). For γ-secretase, ~90 different substrates have been reported, and for SPP, the 
number is ~30, yet a consensus motif for substrate cleavage remains elusive (5,59). 
Substrate sequences exhibit high variability in amino acid sequence and length (87,88). 
Early studies suggested that helix-breaking residues within the TM substrate at or around 
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the cleavage site are required. These residues were proposed to destabilize the TM helix 
and thus serve as a driving force for exposure of the scissile bond to the protease 
(80,89,90). However, this proposal has not persisted, as many canonically helical residues 
have been reported as cleavage sites for IAPs (51,52). Conversely, residues other than 
aspartate within the IAP enzyme that affect catalysis – kinetics, cleavage specificity, 
substrate and water entry – are largely obscure. For example, the specific roles of Tyr and 
Gly within the highly conserved YD…GxGD motif remain to be clarified. Finally, recent 
structures (54,57) do not clarify substrate or water entry. The TM helices proximal to the 
proposed substrate-gating motif PAL (63,151,152) need to undergo a substantial 
conformational change to enable entry of an exogenous TM substrate to the active site, a 
motion that is chemically incompatible with the presence of water in the active site.  
Here in Chapter 3, we compare in vitro kinetic parameters and cleavage sites of 
an IAP ortholog from Methanoculleus marisnigri (mIAP) toward two substrates, one 
fortuitous (angiotensinogen of renin, a soluble aspartyl protease) (56) and one biological 
(fragments of amyloid precursor protein C-terminal segment, C100). Our studies reveal a 
preference for a polar residue, Thr, at the scissile bond. Using the renin substrate, we first 
examined mutants of the YD…GxGD and PAL motifs. We demonstrate that kinetics are 
impaired except in the case of Y161F, and the His-Thr cleavage site dominates (56). 
mIAP cleaves the C100 sequence at Ala-Thr, the so-called γ-secretase ‘γ-site’ (153) 
leading to the formation of Alzheimer-associated amyloid-β species Aβ42 (154), faster 
and with higher affinity in bicelles than renin or C100 in detergent solution. The ortholog 
also cleaves the so-called γ-secretase ‘-site’ corresponding to longer Aβ peptides (153), 
centered around Thr. However, Thr-scanning mutagenesis within the renin substrate 
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reveals cleavage is preferred at the original site, even absent a Thr residue. Our 
systematic biochemical study further refines the features that govern peptide hydrolysis 
by IAPs, providing a foundation for elucidating substrate entry and other mechanistic 
details that better enable the development of selective inhibitors for diseases associated 
with IAP catalysis, such as Alzheimer and Hepatitis C viral infection, without affecting 
processing of substrates for other biological processes.  
3.3 Methods 
3.3.1 Molecular biology 
 The gene sequence for mIAP was cloned into the pet 22b(+) (Novagen) vector 
with C-terminal hexa-histidine tag as described previously (56). MRSWT was cloned in 
pEX-K vector by MWG Operon. Substrates MCSTV (MBP-TVIVITLVML-SUMO) and 
MCSGG (MBP-GGVIVITLVM-SUMO) were cloned into pMAL-c4x and purchased 
from GenScript. Mutations to mIAP, MRS substrates, and MCS were carried out via site-
directed mutagenesis (Agilent QuickChange Lightning kit, primer sequences in (Table 

















Table 3.1. Primers used for site-directed mutagenesis of enzyme IAP and substrates MRS 
and MCS 
IAP mutants Forward (F) and Reverse (R) Primers (5’-3’) 
Y161A F: GCTGCTCGCGGTCGCCGACGCCATATCGGTCTACC 
R: GGTAGACCGATATGGCGTCGGCGACCGCGAGCAGC 
Y161F F: GCTGCTCGCGGTCTTCGACGCCATATCGGTCTACC 
R: GGTAGACCGATATGGCGTCGAAGACCGCGAGCAGC 
D162N F: GCTGCTCGCGGTCTACAACGCCATATCGGTCTACC 
R: GGTAGACCGATATGGCGTTGTAGACCGCGAGCAGC 
G219A F: CGTTCGTCATGGGTATGGCCGATCTCATCATGC 
R: GCATGATGAGATCGGCCATACCCATGACGAACG 
D220N F: CGTCATGGGTATGGGCAATCTCATCATGCCCTCG 
R: CGAGGGCATGATGAGATTGCCCATACCCATGACG 
Q272A F: GTCAACAAGGGCAACCCCGCGGCGGGTCTCCCCCCC 
R: GGGGGGGAGACCCGCCGCGGGGTTGCCCTTGTTGAC 




L275F F: GGGCAACCCCCAGGCGGGTTTTCCCCCCTTAAACGGCG 
R: CGCCGTTTAAGGGGGGAAAACCCGCCTGGGGGTTGCCC 
MRS mutants Forward (F) and Reverse (R) Primers (5’-3’) 
T10L F: CCACCTGGTGATCCACCTCATGTCGGACTCAG 
R: CTGAGTCCGACATGAGGTGGATCACCAGGTGG 
P3T F: GCGCAGACTAATTCGATCCACACCTTCCACCTGGTG 
R: CACCAGGTGGAAGGTGTGGATCGAATTAGTCTGCGC 
L6T F: CACCCCTTCCACACGGTGATCCACACC 
R: GGTGTGGATCACCGTGTGGAAGGGGTG 
P3T, T10L F: GCGCAGACTAATTCGATCCACACCTTCCACCTGGTG 
R: CACCAGGTGGAAGGTGTGGATCGAATTAGTCTGCGC 










Table 3.1 (Continued) 
MRS to 
MCS10 
Forward (F) and Reverse (R) Primers (5’-3’) 




Round 2 F: CAGACTAATTCGATCCACCCCGTCATCGCGGTGATCCACA 
CCATGTCGGA 
R: CCGACATGGTGTGGATCACCGCGATGACGGGGTGG ATC 
GAATTAGTCTG 







Forward (F) and Reverse (R) Primers (5’-3’) 










3.3.2 Expression and purification of enzyme variants and fusion 
substrates 
 Plasmids containing IAP (wild type and variants) were transformed into E. coli 
Rosetta 2 cells (Novagen). Large scale growth of bacteria, membrane isolation and 
protein purification steps were carried out as described previously (56), with the 
following modifications found to improve protein yield: cells were induced with 0.2 mM 
isopropyl-β-D-1-thiogalactopyranoside (IPTG) at OD600nm = 1.5, followed by growth 
overnight at 22°C. During nickel affinity purification, weakly bound impurities were first 
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removed with 5% Buffer B (50 mM Hepes (pH 7.5), 500 mM NaCl, 500 mM imidazole, 
0.1% DDM) before the full gradient was applied. Protein purity after size exclusion 
chromatography (SEC) was assessed by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) (12% polyacrylamide) stained with Coomassie. Pure 
protein was concentrated and exchanged into phosphate-buffered saline (PBS, 10 mM 
sodium phosphate, pH 7.2, 150 mM NaCl) supplemented with 0.05% DDM using a 15 
mL Amicon Ultra 50K MWCO concentrator (Millipore). The protein concentration was 
measured using a ThermoScientific NanoDrop spectrophotometer. The calculated 
extinction coefficient, ε = 33,920 M-1 cm-1, and molecular mass from the amino acid 
sequence were obtained by ExPASy ProtParam (155). 
 Plasmids encoding substrates were transformed into E coli BL21 DE3 (Novagen). 
A single colony was inoculated in 200 mL LB media supplemented with 50 µg mL-1 
kanamycin except for MCSTV and MCSGG, which were supplemented with 60 µg mL-1 
ampicillin. Inoculum was grown overnight in an orbital shaker (225 rpm, 37°C). Large 
cultures (1L) were inoculated with 20 mL of overnight culture and grown until an 
OD600nm = 0.6 – 0.8 was reached. After cooling the cultures to 18°C, protein expression 
was induced with an addition of 1 mM IPTG. Cultures were grown overnight and 
harvested by centrifugation at 5,000 x g followed by flashed-cooling with liquid nitrogen 
to store at -80°C. The purification of substrates proteins was carried out as described 
previously (56) except for MCS15, which was present in a mixture of aggregated and 
monomeric protein. For MCS15, in addition to nickel and amylose affinity 
chromatography, SEC using HiLoad 16/600 Superdex 75 pg was used to further 
fractionate monomer from aggregate. The purity of protein was assessed by Coomassie-
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stained SDS-PAGE (12% polyacrylamide). Pure protein was concentrated and exchanged 
into PBS, 0.05% DDM using a 15 mL Amicon Ultra MWCO 30K concentrator 
(Millipore). Protein was measured on a ThermoScientific NanoDrop spectrophotometer 
using a calculated extinction coefficient, ε = 69,330 M-1 cm-1, as before (155).  
3.3.3 FRET assay and inhibitor studies  
Assays with Ren390FRET (Anaspec) were conducted as described previously 
(56). For C100FRET (Millipore), lyophilized peptide was dissolved in DMSO to generate 
a stock solution at 1250 µM. A working stock solution (500 µM) was prepared by 
diluting the original stock with 10 mM sodium phosphate, pH 7.2, 150 mM NaCl (PBS), 
0.05% (w/v) DDM. The 500 µM C100FRET working stock was sonicated (Branson 
ultrasonics corporation) at 50-60 Hz, 117 V, 0.7 Amp for 30 min prior to being diluted to 
3-40 µM solutions with PBS with 0.05% DDM and dispensed into black-bottomed, non-
binding 96-well plates (Corning). Plates were covered with optical adhesive film (Micro-
Amp) and incubated at 37 °C for 30 min, a process that resolved the initial high 
background from the C100FRET substrate. Freshly purified IAP (0.5 µM, in PBS 0.05% 
DDM and reconstituted inside 5% (v/v) bicelles (56)) was then added to the substrate 
solution in the 96-well plate. The fluorescence readings were acquired every 2 min for 
2.5 h at 37°C in a Synergy H4 plate reader (BioTek, λex = 350 ± 9 nm, λem = 440 ± 9 nm). 
The initial velocity was determined from the fluorescence readings over the first 2 h. The 
background reading at each substrate concentration was subtracted and the fluorescence 
reading was converted from arbitrary fluorescence unit (Afu) to concentration of product 
(nM) by using the standard calibration curve of free NMA. The inner filter effect was not 
observed for the NMA-DNP donor-acceptor pair. GraphPad Prism 5 software was used 
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for Michaelis-Menten kinetic analysis as described previously (56). Twelve replicates 
from independent batches of cell paste and enzyme purification were used in data 
analysis.  
 For inhibitor studies, (ZLL)2ketone (Calbiochem) was dissolved in DMSO to 
prepare 1 mM stock. (ZLL)2ketone was diluted to a final 2- to 10-fold molar excess of the 
enzyme in the activity assay and preincubated with purified enzyme for an hour at 37°C. 
C100FRET was then added and the assay conducted as above. Kinetics data of nine 
independent replicates were analyzed as described above.  
3.3.4 Gel-based assay 
  Varying concentrations of mIAP (1-8 µM), prepared in PBS with 0.05% DDM or 
5% (v/v) bicelle, were incubated with MCS10 (5 µM) at 37°C for 24 h. For time course 
experiments, 16 µM of mIAP was incubated with MCS10 (5 µM) and the reaction was 
quenched at different time points by adding equal volume of Laemmli SDS-PAGE 
sample loading dye containing β-mercaptoethanol, followed by storage at -20 °C. For 
experiments with (ZLL)2ketone, a range of inhibitor concentration (8-32 µM) was pre-
incubated with 16 µM of IAP at 37°C before adding MCS10 (5 µM). The cleavage 
reaction samples were separated by SDS-PAGE (12% (w/v) polyacrylamide) followed by 
transfer onto polyvinyl difluoride (PVDF) membrane (MilliPore). Standard Western blot 
procedures were performed using MBP-probe mouse monoclonal IgG primary antibody 
(Santa Cruz, 1:1000) and horseradish peroxidase (HRP)-conjugated goat anti-mouse 
monoclonal IgG secondary antibody (KPL, 1:5000). The PVDF membrane was sprayed 




 For LC-MS analysis, gel assay was set up as described above except that ice-cold 
acetone (6.5 x sample volume) was added to quench reaction at 24 h for samples 
containing MCS10 substrate and at 24 h and 48 h for sample containing MRS substrate, 
followed by storage at -20 °C. After decanting the acetone, samples were analyzed by 
SDS-PAGE. LC-MS analysis of samples was carried out as described previously (56) 
with the following modifications.  An UltiMate™ 3000 RSLCnano System UPLC system 
(Dionex) was couples to a Q Exactive Plus Mass Spectrometer (Thermo Scientific). The 
Mascot Search engine (Version 2.6.0) was used with Proteome Discoverer 2.1 (Thermo 
Scientific).  Only peptide spectral matches with expectation value of less than 0.01 
(“High Confidence”) were used.    
 For isotopic 18O labelling, first PBS with 0.05% DDM (75 µL) was lyophilized in 
a Speed Vac (Savant) for 30 min, after which 75 µL of heavy water H2
18O (Cambridge 
Isotopes) was added. Purified mIAP (16 µM) and either MRSWT or MCS10 (5 µM) was 
then added to run gel-based assay at 37°C for 24 h. LC-MS analysis of samples was 
carried out as described above.  
3.3.5 CD  
CD spectra and thermal melts were acquired on a Jasco J-810 spectropolarimeter 
equipped with Neslab RTE 111 circulating water bath and a Jasco PTC-4245/15 
temperature control system using a 0.1-cm cuvette. CD spectra of IAP variants (5 µM in 
20 mM HEPES (pH 7.5), 250 mM NaCl, 0.05% DDM) were acquired from 300-200 nm 
at room temperature. Data were blank-subtracted and converted to molar ellipticity Ɵ = 
(Ɵobs x 10
6)/(pathlength (mm) x c x n), where Ɵobs is the observed ellipticity (mdeg) at 
wavelength λ; c is the protein or peptide concentration (μM); and n is the number of 
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residues. CD thermal melt was performed with a 1 °C min-1 increase in temperature from 
5 to 89°C. Both CD spectra and thermal were acquired with 15 averaged scans from 300-
200 nm at a 200 nm min-1 scan rate. Data at 222 nm were blank-subtracted, converted to 
molar ellipticity and plotted against temperature in GraphPad Prism 5. 
3.3.6 SAXS and ab initio modeling  
SAXS data for substrate solutions containing ~1 mg/mL of substrate in 20 mM 
Hepes (pH 7.5), 250 mM NaCl were collected at 12°C using a Rigaku BioSAXS-2000 
instrument with 2D Kratky collimation and a rotating Cu anode X-ray source (λ = 
1.54187 Å). Each sample was exposed for a total of 3 hours using multiple scans to 
confirm consistency between measurements and the absence of radiation damage. 
Matched buffers measured at an identical instrument configuration were used for 
background subtraction. Rigaku SAXSLab software was used for data reduction, and 
yielded a 1D plot of the scattered intensities over the range of momentum transfer 0.0104 
< q < 0.6782Å-1 [q = 4π sin(θ)/λ, 2θ is the scattering angle and λ is the X-ray 
wavelength]. 
Three-dimensional reconstruction of the substrate structure from the SAXS data 
was performed using the ATSAS software suite (156). Briefly, the pair-distribution 
function P(r) (using 0.0104 < q < 0.3464Å-1) was determined from an indirect Fourier 
transform of the scattering data for each substrate via GNOM. The DAMMIF tool was 
then used to rapidly generate 17 compact bead representations of the scattering particle. 
This initial collection of models was clustered using DAMCLUST, and the averaged 
model from the most populated cluster was used with DAMSTART to generate a fixed 
core (using a cut-off volume of one half the excluded volume of the particle) for further 
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refinement in DAMMIN. Ten refined models from DAMMIN (slow-mode) were 
similarly clustered, and a representative model of the most populated cluster was 
compared to results from a rigid-body model reconstruction. CORAL was employed for 
rigid-body modeling, performing translation and rotation of high-resolution PDB 
structure fragments, as well as constructing dummy atom segments of defined lengths 
linking between domains and at the C-terminus. MBP used for rigid-body modelling was 
excised from PDB 5CL1, chain A: residues 1-368. The structure for the SUMO domain 
was taken from the first of 20 conformers in the collection of NMR structures deposited 
under PDB 1L2N; the first 20 and C-terminal 5 amino acids are absent in the NMR 
structure. Dummy atom representations of the linker region containing the substrate 
target sequence, omitted residues of the SUMO domain, and C-terminal hexahistidine-tag 
were all constructed using CORAL. 
3.4 Results 
3.4.1 Enzymatic analysis of mIAP mutants 
To assess contributions of particular residues to catalysis (Table 3.2, Figure 3.1A, 
see below), we employed a continuous kinetics FRET peptide assay in combination with 
a discontinuous gel-based assay, methodology we reported previously (56). Kinetic 
assays with mIAP variants were conducted using the fortuitous renin 390 FRET peptide. 
Due to the incompatibility of the FRET assay components with mass spectrometry 
analysis, we turned to a gel-based assay that uses a fusion protein (MRSWT) in which the 
renin substrate IHPFHLVIHT is flanked by E. coli maltose binding protein (MBP) and 
yeast small ubiquitin-like modifier (SUMO). Cleavage profiles from a gel-based assay 
are analyzed by liquid chromatography tandem mass spectrometry (LC-MS) analysis 
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(56). In aqueous solution, MRSWT adopts an elongated structure as visualized by the 
small angle X-ray scattering (SAXS) envelope (Figure 3.1B, Figure 3.2), rendering the 
desired 10-residue angiotensinogen sequence (IHPFHLVIHT10) accessible to detergents 
and mIAP. 
 
Table 3.2. Rationale of mIAP mutation and kinetics parameters associated with each 
mutant. 








(μM-1 min-1)  
WT  7.8 ± 0.7 4.1 ± 0.1 8.1 ± 0.3 1.0 ± 0.1 
Y161A Catalytic YD162 
motif 
8.9 ± 0.8 1.8 ± 0.1 3.6 ± 0.2 0.40 ± 0.04 
Y161F Catalytic YD162 
motif 
5.8 ± 0.5 3.6 ± 0.1 7.2 ± 0.6 1.2 ± 0.5 
G219A Catalytic 
GxGD220 motif 
9.4 ± 0.6 2.4 ± 0.2 4.8 ± 0.2 0.51 ± 0.04 
Q272A Substrate gating 
QAGL275 motif.  
6.2 ± 0.6 1.6 ± 0.1 3.2 ± 0.1 0.52 ± 0.05 





4.9 ± 0.7 0.51 ± 0.04 1.0 ± 0.4 0.21 ± 0.05 
L275F FAD mutation 










Figure 3.1. Characterization of mIAP mutants. (A) Superposition of mIAP (PDB ID 
4HYC, cyan) and presenilin (PDB 5A63 chain B, magenta) structures using secondary 
structure matching (157). TM helices are numbered from N- to C-terminus. Key sequence 
motifs highlighted. AS= active site. (B) Ab initio model of MRSWT obtained by SAXS. 
(C, D, E) Michaelis-Menten kinetic analysis of mIAP variant cleavage of Ren390FRET. 
(F) Gel assay of mIAP mutants using MRSWT substrate. Negative control without enzyme 
is indicated by (-). The uncut substrate and cleavage products (indicated by arrow) are 
detected via anti-MBP Western blot. (G, H) Cleavage profiles of MRS substrate were 
generated by Glu-C digestion of the N-terminal product, facilitated by a C-terminal Glu 
within MBP (black triangle). Major cleavage site is His9-Thr10 (red triangle). The relative 
abundance of each reporter peptide, compared to total peptide spectral matches (PSMs) 
of seven independent peptide products formed by proteolytic cleavage, is shown. Error 
bars represent the standard deviation from LC-MS analytical replicates. (I) LC-MS 
spectrum of reporter peptide (z=3) displaying 350% more 18O incorporation than 16O. 
(Left) The extracted ion current (XIC) for relative abundance of peptide 
(ALKDAQTNSIHPFHLVIH) with 16O incorporation (middle) versus 18O incorporation 
at the C-terminal of N-terminal product (right) from enzymatic cleavage. Approximately 




Figure 3.2. SAXS analysis of MRSWT substrate. (A) Buffer-subtracted SAXS I(q) data 
for MRS at concentration of ~1 mg mL-1. The linear region of the Guinier plot at low-q 
(right) and the residuals from the fit to the experimental data, such that q·Rg < 1.3, yield a 
radius of gyration (Rg) of 33.6 ± 0.2 Å for MRSWT. (B) A Kratky plot of these same data 
indicates that MRSWT is well folded. (C) The pairwise distance distribution function P(r) 
yields a maximum particle dimension (Dmax) of 141 Å. The shape of the P(r) function 
suggests an elongated molecule, or extended domain. 
 
mIAP variants Y161A, Y161F, and G219A within the YD162…GxGD220 motif 
and Q272A, L275F on the C-terminal helix near the presenilin PAL motif (Table 3.2) 
were purified and biophysically characterized as for wild-type (WT). Like WT, all mIAP 
mutants exhibit α-helical signatures (Figure 3.3). Although the thermal melts did not 
yield a sigmoidal curve, both WT and mutants display similar curves, indicating relative 




Figure 3.3. Biophysical characterization of mIAP mutants. (A) Circular dichroism (CD) 
spectra of WT IAP and mutants acquired at 4°C. (B) CD thermal melts over the range of 
5-90°C, monitored at 222 nm. 
 
Kinetic and cleavage site profiling reveal that mIAP is largely tolerant to 
mutation, with primary defects observed in catalytic efficiency and details of 
processivity. The only variant tested that exhibits Michaelis-Menten kinetic properties 
indistinguishable from WT is mIAPY161F, representing the Tyr in the Y161D catalytic 
motif (Figure 3.1C, Table 3.2). This result indicates that the phenyl ring, but not the 
hydroxyl group, is the relevant chemical feature needed for catalysis. This result is 
surprising given the dearth of hydrogen bond donor/acceptors in the active site that might 
be capable of activating water or stabilizing an anionic tetrahedral intermediate during 
hydrolysis. In support for the importance of the phenyl ring, catalysis by mIAPY161A is 
impaired, with a reduced Vmax and two-fold lower catalytic efficiency (Figure 3.1C, 
Table 3.2). The catalytic motif mutant, mIAPG219A, adjacent to the aspartate in GxG219D, 
and the site of the familial Alzheimer disease (FAD) mutant G384A in presenilin 
(158,159), exhibits catalytic rates similar to mIAPY161A (Table 3.2). Previous studies of 
the G384A presenilin variant (160) and corresponding variant in other SPP homologs 
(52,161) detected reduced end product via immunoblot. Consistent with our 
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measurements (Table 3.2), one additional study of the G384A presenilin variant reported 
two-fold reduced Vmax compared to WT enzyme (162). While rigidifying this region 
with the G219A substitution is detrimental to optimal orientation of Asp220 for catalysis, 
it is noteworthy that the reaction still proceeds.  
In terms of substrate entry, replacing the mIAP sequence AGL275 with PAL435 
found in presenilin (63,151,152) reduces catalytic efficiency by ~80% compared to WT, 
indicating PAL is not a favorable substitute (Figure 3.1D, Table 3.2). For mIAPL275F, 
corresponding to the presenilin L435F FAD mutant (107,163,164), catalytic efficiency is 
similar to WT, but this is due to the countering effect of a ~60% decrease in Vmax 
combined with 50% improvement in Km (Figure 3.1D, Table 3.2). More favorable 
substrate binding to the enzyme when the aromatic Phe is present appears to be 
unfavorable to some aspect of catalysis. For mIAPQ272A, immediately N-terminal to 
AGL275, catalytic efficiency is half of WT due to decreased Vmax. Km remains near 
that of WT (Figure 3.1D, Table 3.2), so this residue appears not to modulate substrate 
binding and may instead play a cursory role in positioning other helices for catalysis. 
 Given the sensitivity of our FRET assay in detecting low levels of cleavage for 
the aforementioned variants, we tested the hypothesis that polar Asn in place of the 
negatively charged Asp residues supports catalysis. Each of the catalytic mutants, 
mIAPD162N, mIAPD220N, and the double mutant (DM) mIAPD162N/D220N were 
found to be inactive (Figure 3.1E). Thus, the specifically charged state(s) of the aspartic 
residues are critical for mIAP proteolysis.  
Variants of mIAP exhibiting measurable activity in the FRET assay cleave 
MRSWT (Figure 3.1F) with profiles that mirror WT mIAP, namely, a predominant cut site 
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at His9-Thr10 (Figure 3.1G,H, Figure 3.4, Supplementary Table S1.xlsx). However, 
differences in overall cleavage profiles suggest that members of the YD…GxGD and 
PAL sequence motifs proximal to the catalytic aspartates (Figure 3.1A) influence 
processivity of IAP cleavage when presented with the renin substrate. For example, 
mIAPL275F displayed higher cleavage site specificity than WT, with little to no product 
at positions His5-Leu6, Ile8-His9, Thr10-Met (from SUMO, not in Ren390FRET). Thus, 
tighter substrate binding by mIAPL275F, reflected in the lower Km value in the FRET 
assay, appears to be detrimental to processivity. In addition, for WT-like mIAPY161F, 
cleavage at Thr10-Met11, the second-most preferred site for WT and beyond the 
sequence harbored by Ren390FRET, is substantially diminished. 
 
 
Figure 3.4. All LC-MS replicates for MRS substrates cut by mIAP mutants. MRS 
cleavage profile processed by (A) WT mIAP, (B) Y161A, (C) Y161F, (D) G219A, (E) 
Q272A, (F) L275F. For each mutant, B1, biological replicate 1; B2, biological replicate 
2; A1, analytical replicate 1; A2, analytical replicate 2. Relative product abundance 




3.4.2 Role of bulk water in mIAP catalysis 
 In the case of soluble aspartyl proteases, water is activated for nucleophilic attack 
(165). To test for incorporation of bulk water in mIAP catalysis, we carried out the 
MRSWT cleavage reaction in the presence of 75% heavy water H2
18O. LC-MS analysis of 
the resulting cleavage products reveals robust 18O incorporation at the C-terminus of the 
cleavage products, exceeding the observed 16O incorporation in the expected proportion 
(Figure 3.1I). To our knowledge, this isotope partitioning experiment is the first to 
provide direct evidence for a role for bulk water in an IAP. 
3.4.3 mIAP cleavage of the presenilin C100 substrate in the ‘γ-site’ 
region 
 Kinetic analysis of mIAP was expanded next to a second substrate, C100FRET, 
which contains the ‘γ-site’ from the γ-secretase C100 substrate (GGVVIATV flanked by 
N-methyl anthranilate (NMA fluorophore) and lysine-modified with 2-nitrophenol (DNP) 
quencher, followed by triple D-Arg) associated with Aβ42 production. Adaptation of our 
continuous assay for this substrate was straightforward; the initial velocity is sustained 
over the first 2 h of the incubation, and arbitrary fluorescence units (Afu) were converted 





Figure 3.5. C100FRET assay development. (A, B) Determination of initial velocity 
region from 20 h assay. Fluorescence readings for mIAP incubated with different 
concentrations of C100FRET are detected for 20 h. Initial velocity is within the first 2 h. 
(C) Standard calibration curve of NMA plotting the background-subtracted arbitrary 
fluorescence unit (∆Afu) against concentration of NMA (nM). 
 
Reactions of mIAP and C100FRET were conducted in n-dodecyl--D-maltoside 
(DDM) and bicelles. mIAP cleaves C100FRET with similar Vmax in detergent and in 
bicelles, but Km is notably more favorable in bicelles (Figure 3.6A, Table 3.3). As 
expected, catalytic mutants mIAPD162A, mIAPD220A, and mIAPD162A/D220A failed to cleave 
C100FRET (Figure 3.6A) and (ZLL)2ketone is a competitive inhibitor of WT mIAP, with 
the same Ki value we reported previously (56) (Figure 3.6B). For reactions in DDM, 
Vmax is nearly four-fold faster and Km is 20% lower for C100FRET compared to 
Renin390FRET, resulting in ~5-fold higher catalytic efficiency (Table 3.2). In bicelles, 
the catalytic efficiency is even more pronounced for C100FRET, 15-fold higher more 
efficient compared to Renin390FRET. The reason for the dramatic efficiency difference 
is not immediately obvious, but is consistent with the idea that C100FRET derives from a 
biological substrate whereas Ren390FRET, while competent for catalysis, is not tailored 
to IAPs. Overall, our Km is in the typical low micromolar range, similar to the soluble 
aspartyl protease renin (134), but mIAP is much less efficient. Prior studies using this 
substrate to study γ-secretase kinetics did not place absolute scale (166,167), so direct 
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comparisons are not possible. In other studies, where initial rates were evaluated via 
immunoblot quantitation after a set incubation time, our Km is either 10-fold weaker 




Figure 3.6 mIAP cleavage of C100 -site. (A) Michaelis-Menten kinetic analysis of 
C100FRET cleavage by WT mIAP in DDM and bicelles, and by catalytic mutants 
(D162A, D220A, and DM) in DDM. (B) Kinetic data for mIAP treated with increasing 
(ZLL)2ketone. (C-G) Gel assay using MCS10 and mIAP, visualized by anti-MBP 
immunoblot. (C) Time course in DDM. (D) Time course in bicelles. (E) Product 
formation as a function of mIAP concentration. (F) Inhibition by (ZLL)2ketone. (G) 
mIAP variants D162A, D220A, and DM are not active. Negative control without enzyme 
is indicated by (-). The uncut substrate and cleavage product (indicated by arrow) are 
detected as in Figure 3.1. All LC-MS data are presented in Supplementary Table S2.xlsx. 
(H) LC-MS analysis of MCS10 cleavage sites by mIAP in DDM and bicelles, compared 





Table 3.3 Kinetic parameters obtained from mIAP cleavage of C100FRET in DDM and 
bicelles and effect of (ZLL)
2
ketone inhibitor 
  Enzyme  Inhibitor  K
m
 (µM)  V
max 
 





















  IAP 
(DDM) 
  IAP 
(bicelles) 
          - 6.0 ± 0.7 
 
1.7 ± 0.1 
15.9 ± 0.6 
 
13.2 ± 0.2 
32 ± 1  
   
26 ± 1  
5.3 ± 0.9 
 
16 ± 1 
  
  IAP 
  IAP 








10 ± 1 
13 ± 2 
17 ± 2  
  
15.8 ± 0.9  
15.9 ± 0.9  
15.5 ± 0.8  
  
  32 ± 2 
  32 ± 2 
  31 ± 2 
  
  3.0 ± 0.7 
  2.5 ± 0.3 
  1.8 ± 0.3 
 
  
To identify the cleavage site within the C100FRET sequence, we adapted our gel 
assay by generating MCS10, an analogous substrate in which the intervening sequence 
between MBP and SUMO in MRSWT was converted to G37GVVIATVIV48. MCS10 
contains the octapeptide sequence of C100FRET plus two more, IV48, from C100. An 
increase in the N-terminal product was observed over the course of a 2-24 h reaction 
period in DDM (Figure 3.6C). Paralleling results from C100FRET, the reaction between 
mIAP and MCS10 in bicelles was faster than in DDM, as product was readily visible 
within 30 minutes followed by a continued increase over the duration of the experiment 
(Figure 3.6D). As expected, the reaction is dependent on IAP concentration, is inhibited 
by (ZLL)2ketone, catalytic mutants mIAPD162A, mIAPD220A and DM mIAPD162A/D220A are 
unable to cleave MCS10, and the substrate remains stable throughout the time course of 
the experiment (Figure 3.6E-G). LC-MS cleavage profiles for MCS10 reveal highly 
specific cut sites – Ala42-Thr43 and Thr43-Val44 – both in DDM and bicelles (Figure 3.6H, 
Figure 3.7A, Supplementary Table S2.xlsx). Isotope partitioning again demonstrates the 
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use of bulk water in the mIAP reaction (Figure 3.8). In sum, like results for mIAP 
cleavage of the MRSWT substrate, these data indicate the involvement of a site-adjacent 




Figure 3.7. All LC-MS replicates for MCS-related substrates cut by mIAP WT. (A) 
Cleavage profile of MCS10. (B) Cleavage profile of MCSTV. (C) Cleavage profile of 
MCSGG. For each substrate, B1, biological replicate 1; B2, biological replicate 2; A1, 
analytical replicate 1; A2, analytical replicate 2. Relative product abundance quantified as 




Figure 3.8. MS analysis of MCS10 substrate incubated with mIAP in H2
18O. (A) MS 
spectrum of doubly charged (z=2) reporter peptide displaying 50% more 18O 
incorporation than 16O. (B, C) The extracted ion current (XIC) for relative abundance of 
peptide (ALKDAQTNSGGVVIA) with 16O incorporation (B) versus 18O incorporation 
(C) at the C-terminal of N-terminal product from enzymatic cleavage. Approximately 
14.2% of peak at 723.3956 is due to two-13C isotope of the 16O-containing peptide. 
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 The identified cleavage positions for mIAP reacted with MCS10 recapitulates the 
γ-secretase γ-site cut site leading to Alzheimer-associated Aβ42 and Aβ43 production but 
we did not detect even low-level background cleavage at Ile-Ala corresponding to the γ-
secretase cleavage product Aβ40 (153). Our results differ from a previous study 
indicating that the same mIAP ortholog cleaves epitope-tagged C100 to release 
predominantly Aβ38 and Aβ40, with only a minor product of Aβ42 (53), but kinetics 
were not investigated in that system. Perhaps endoproteolysis of presenilin (168), which 
was not observed for our mIAP, confers the ability to robustly produce Aβ40.  
3.4.4 mIAP cleavage of the presenilin C100 substrate in the ‘-site’ 
region  
Prior to γ-site cleavage presenilin has been shown to cleave at the C100 ‘-site’, 
which generates Aβ48-49 (153). After unsuccessful attempts to generate a fusion 
substrate containing both sites (MBP- G37GVVIATVIVITLVM-SUMO, MRS15) due to 
substrate aggregation (Figure 3.9), the isolated -site was probed by two fusion substrates 
shifted registers, MCSTV (MBP-T43VIVITLVML-SUMO) and MCSGG (MBP-GG-
V44IVITLVM-SUMO) (Figure 3.10A), which includes the flexible Gly-Gly hinge 
thought to help position ε-site in the active site of γ-secretase (169). IAP cleaves both 
substrates (Figure 3.10B) LC-MS analyses converge on cut sites at three consecutive 
peptide bonds. The predominant cut site is Thr48-Leu49 (Figure 3.10C, D, Figure 3.7B, 
C, Supplementary Table S2.xlsx), which corresponds to presenilin-associated peptide 
Aβ48. Whereas the Thr residue of MCS10 γ-site and MCSGG -site are in register 
(Figure 3.10C), comparison of MCSTV and MCSGG, which are offset, further supports a 





Figure 3.9. Gel assay using MCS15 substrate. (A) Western blot analysis using anti-MBP 
antibody. A 45 kDa band and high molecular weight species are present in MCS15 after 
purification even in the absence of IAP. With IAP addition, high molecular weight 
aggregates are seen immediately, which then grow over the course of 24 h at 37 °C. (B) 
Corresponding Western blot using anti-hexahistidine antibody detection recapitulates 
results in (A) but demonstrates the presence of the His-tagged mIAP (~25 kDa) (C) 
Coomassie-stained SDS-PAGE gel showing IAP and MCS15 at the end of 24 h gel assay. 
 
 
Figure 3.10. mIAP cleavage of C100 -site. (A) Overlay of substrates used in this study 
and relationship to C100 γ- and - cleavage sites of γ-secretase. (B) mIAP gel assay using 
MCSTV and MCSGG substrates. (C, D) MS analysis of MCS10, MCSGG and MCSTV 




3.4.5 Probing substrate specificity by Thr-scanning within the MRS 
substrate  
To further address the interplay between chemical and positional preferences for 
mIAP cleavage, we introduced Thr substitutions adjacent to His residues in MRSWT 
(IHP3FHL6VIHT10), namely, replacing P3 or L6 with Thr, and either retaining or 
removing the original His9-Thr10 cut site (MRSP3T, MRSP3T/T10L, MRSL6T, MRSL6T/T10L, 
Figure 3.11A and (56)). Since cleavage at His5-Leu6 was of low abundance in MRSWT, 
we predicted that replacing Thr10 in MRSWT with Leu (MRST10L) would disfavor this 
position as a cleavage site, and serve as a control for positional preference (Figure 
3.11A). mIAP cleaves all five MRS Thr-scanning mutants, including MRST10L where no 
H-T is present (Figure 3.11B-E, Figure 3.12,  Supplementary Table S2.xlsx). The major 
cleavage position remains the same as for MRSWT, and does not preferentially shift 
internally for MRSL6T, MRSL6T/T10L (Figure 3.11D), MRSP3T or MRSP3T/T10L (Figure 
3.11E). Thus, in contrast with C100 -site cleavage, positional preference presides over 




Figure 3.11. Probing substrate specificity of IAP using MRS Thr-scanning mutants. (A) 
Sequences generated for this study. (B) Gel cleavage assay using mIAP and MRS 
substrate variants, visualized by anti-MBP immunoblot. (C, D, E) Corresponding LC-MS 
analysis of reactions from (B) with quantification and presentation as in Figure 3.1. All 





Figure 3.12. All LC-MS replicates for MRS mutant substrates cut by mIAP WT. (A) 
Cleavage profile of MRST10L. (B) Cleavage profile of MRSP3T. (C) Cleavage profile of 
MRSP3T/T10L. (D) Cleavage profile of MRSL6T (E) Cleavage profile of MRSL6T/T10L. For 
each substrate, B1, biological replicate 1; B2, biological replicate 2; A1, analytical 
replicate 1; A2, analytical replicate 2. For MRSL6T/T10L a third biological replicate (B3) 
was analyzed. Relative product abundance quantified as described in Figure 3.1. Raw 
data in Supplementary Table S2.xlsx. 
 
3.5 Discussion 
Intramembrane proteolysis must be highly regulated in the cell (2), yet contrary to 
intuition and knowledge of soluble proteases (119,120), data to date do not converge on 
recognition motifs for IPs within their TM substrate. Cleavage of non-physiological 
substrates has been demonstrated in vitro for S2P (90), IAPs (51-53), rhomboid 
(10,31,32), and γ-secretase (147). The biological significance of identified substrates is 
not always clear (170). Related, while helix-breaking residues within the TM segment 
were once thought to be important for cleavage (33,34,80,90), examples to the contrary 
appear in the literature (51,52). Confounding the puzzle for IAPs is an additional 
characteristic of processivity, or ratcheting, of cleavage; that is, IAPs cleave at multiple 
cut sites, and/or trim TM helices to smaller segments that can eventually be released from 
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the membrane (171-173). Systematic in vitro studies using purified enzymes, such as 
ours, can help clarify the physicochemical preferences of IAPs toward their substrates  
Overall, our results point to faster kinetics and higher degree of specificity for 
IAP cleavage than previous studies using other methods. Across the substrates examined, 
a chemical preference for Thr at the scissile bond emerged, regardless of enzyme or 
substrate variant used. None of the residues targeted for mutagenesis within mIAP 
substantially altered cleavage profiles, even where kinetic parameters that might be 
correlated with specificity, such as Km, were altered. Processivity was largely confined 
to residues adjacent to Thr on the substrate, and almost no background cleavage was seen 
for the biological mIAP substrate compared to the fortuitous renin substrate. Finally, bulk 
water is incorporated into the product of the hydrolysis reaction, confirming that the 
chemical reaction is similar to that of soluble aspartyl proteases (165), but how water 
enters the active site, and the extent to which each Asp functions in a manner similar to 
those in soluble aspartyl proteases, remain to be elucidated.  
mIAP activity toward the presenilin substrate C100FRET is five-fold more 
efficient than the fortuitous Ren390FRET, reflected in faster Vmax and lower Km. There 
is no difference in cleavage profiles of MCS10 in bicelle or DDM indicating that the 
presentation of MCS10 to mIAP within DDM micelles and bicelles, and subsequent 
cleavage processes, are similar. Yet, the Km is significantly more favorable for the 
reaction in bicelles, which contains CHAPSO, a cholesterol mimic. Cholesterol is a 
modulator of both membranes (174,175) and C100 catalysis (176-180). Indeed, C100 is 
partitioned well inside the lipid bilayer and specifically binds cholesterol (176). 
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Our study delineates properties and/or roles for specific residues on the enzyme 
beyond the catalytic Asp. The bulky phenyl ring, but not the hydroxyl group, in the YD162 
motif on TM helix 6 seems to be the important chemical property at this position. Y161 
could orient the substrate in the active site, or it may stabilize residues from another TM 
helix in the conformation that supports substrate binding. Reinforcing the need for an 
aromatic residue, but not a proton donor/acceptor at this position, inspection of hundreds 
of presenilin-like proteins (PFAM PF01080 (181)) reveals that the WD motif is found an 
alternative to YD (not shown). Likewise, on TM helix 9, both A273P/G274A and L275F 
within the PAL motif exhibit slowed kinetics, but the Km is better than for WT. In our 
pseudo first order reaction setup, the Km reflects all of the binding events prior to 
catalysis, which is the slow step. Thus, since the substrate has higher affinity for the 
mutant enzyme than WT mIAP, impaired hydrolysis rates reflect a problem later in the 
process, for example, enabling a conformational change or properly that helps properly 
orient the substrate for catalysis.  
 The finding that mIAP exhibits a chemical preference for Thr at the scissile bond, 
when present, is consistent with numerous studies of γ-secretase and C100 describing γ- 
or ε-site cleavage, but the specificity with which mIAP cleaved at these sites containing a 
Thr across several substrates was unexpected. Thr exhibits average helical propensity 
(182-184), but intrahelical hydrogen bonds from the Thr side chain induces a more 
significant bend (185) and thus can displace remaining residues traversing the lipid 
membrane. Other residues capable of forming intrahelical hydrogen bonds include Ser 
and Cys (185). TM segments of SPP substrates (preprolactin, HLA-A*0301, and 
Hepatitis C virus), and γ-secretase substrates (ErbB4, Notch, p75, Delta, Jagged, and 
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STIM1 (74,76,136,186-190)), harbor Thr, Ser, and Cys residues, but most are not 
obviously in register with Thr residues in C100. A positional preference relative to the 
membrane competes for the chemical preference, as demonstrated by the observation that 
mIAP cleaved all Thr-scanning substrates at the same position as H-T in MRSWT. 
Notably, in the case of the Notch, the position of cleavage reported previously for 
presenilin (191) is similar to that of T48-L from C100 (176) with respect to the membrane 
bilayer (not shown). Our data point to a likelihood of different categories of IAP 
substrates governed by disparate physicochemical properties. This and other patterns 
regarding processivity will likely emerge upon further studies with more substrates and 
other IAP family members, ultimately leading to the ability to better target substrates 













4 Chapter 4: Solution structure of an intramembrane aspartyl protease via small 
angle neutron scattering 
 
4.1 Publication and author contributions 
The data presented in Chapter 4 has been published in Biophysical Journal with a 
citation: Naing, S. H., Oliver, R. C., Weiss, K. L., Urban, V. S., and Lieberman, R. L. 
(2018) Solution Structure of an Intramembrane Aspartyl Protease via Small Angle 
Neutron Scattering. Biophysical journal 114, 602-608. Membrane protein deuteration and 
growth was carried out by Kevin Weiss. The protonated and deuterated membrane 
protein were purified by Swe Htet Naing under the guidance of Dr. Raquel Lieberman. 
The small angle neutron scattering (SANS) data collection was performed by Swe Htet 
Naing, Ryan Oliver and Volker Urban. SANS data analysis and ab initio modelling was 
performed by Ryan Oliver and Volker Urban. 
4.2 Introduction 
Despite their broad biomedical reach, the structure of active IAPs including the 
number of subunits in the functional enzyme, has remained ambiguous. Membrane 
proteins require the presence of a mild detergent or other amphiphilic system to solubilize 
and stabilize a given membrane protein in an active conformation, which hinders 
structural characterization using standard analytical techniques used for soluble proteins 
such as size exclusion chromatography (SEC) or small angle X-ray scattering (SAXS). In 
the case of SEC, even coupled with multi-angle light scattering, molecular mass 
determination is only possible when the protein-detergent complex is well separated from 
empty micelles (192), and in SAXS, the signal from the membrane protein cannot be 
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isolated from that of the solubilizing agent (193).  For IAPs, stoichiometries of one (57) 
through eight (194) subunits have been proposed. Prior to recent cryo-electron 
microscopy studies of γ-secretase that indicate a monomer (57), homodimer (145,195-
197) was the predominant proposal. Fluorescence lifetime imaging microscopy was used 
to demonstrate that both SPP (145,196) and presenilins (195,196) are dimers. The lattice 
arrangement of the 3.8 Å resolution crystal structure of the microbial M. marisnigri IAP 
(WP_011844759.1, MmIAP) ortholog suggests either a dimer or tetramer (54).  
 To date, no IP has been structurally characterized using small angle neutron 
scattering (SANS), a method well-suited to study the solution properties of 
macromolecules and complex multicomponent assemblies like membrane proteins (198). 
For membrane protein-detergent complexes, the different scattering length densities 
(SLDs) of each component can be exploited so that only the membrane protein is 
visualized during the scattering experiment. Typically, the SLDs of the detergent and 
buffer/solvent are matched by judiciously adjusting the ratio of H2O and D2O in the 
solvent (199) and the signal from the membrane protein can be further enhanced by 
deuteration during cell growth (198).  
 Here we report the solution structure of deuterated MmIAP in n-dodecyl-β-D-
maltopyranoside (DDM) determined by SANS. After deuterating MmIAP, the detergent 
was fully contrast matched using a specific ratio of hydrogenated and tail-deuterated 
detergent, and the scattering profile for MmIAP was recorded. The radius of gyration 
(Rg) calculated for MmIAP from SANS is smaller than the Rg calculated from the 
crystallographic MmIAP monomer, suggesting a more compact protein in DDM-
containing solution. Our SANS study provides new insight into the solution oligomeric 
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state of MmIAP in detergent solution, as well as bolsters the utility of SANS to 
characterize other IPs and their membrane-bound substrates.  
4.3 Methods 
4.3.1 Expression and Purification of Protonated and Deuterated 
MmIAP 
The plasmid containing MmIAP with a C-terminal hexahistidine tag was 
transformed into E. coli Rosetta 2 cells (Novagen, Madison, WI), grown, membrane 
isolated, and protein purified as described previously for enzyme activity assays(56) 
Modest modifications were made to scale purification to the higher protein requirement 
for SANS experiments. Membrane (~2 g) was solubilized in 160 mL of 50 mM Hepes 
(pH 7.5), 500 mM NaCl, 20 mM imidazole and 1% (w/v) DDM (Anatrace, Maumee, 
OH) by gentle rocking for 1 hr at 4 °C. Unsolubilized material was removed via 
ultracentrifugation at 162,000 x g for 45 min. The supernatant containing solubilized 
membranes was loaded onto a 1-mL HisTrap FF Crude Nickel affinity chromatography 
column (GE Healthcare, Chicago IL) pre-equilibrated with Buffer A (50 mM Hepes (pH 
7.5), 500 mM NaCl, 20 mM imidazole, 0.1% DDM). Prior to elution of MmIAP, weakly 
bound impurities were removed with 5% Buffer B (50 mM Hepes (pH 7.5), 500 mM 
NaCl, 500 mM imidazole, 0.1% DDM). Elution of purified MmIAP was accomplished 
using a linear gradient by mixing Buffer A and 5-60% Buffer B. Elution fractions 
containing MmIAP were pooled and further purified on a HiPrep 16/60 Sephacryl-S300 
(GE Healthcare) using gel filtration buffer (20 mM Hepes (pH 7.5), 250 mM NaCl, 
0.05% DDM). Purity of protein was assessed by denaturing sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) analysis (12% polyacrylamide) stained 
85 
 
with Coomassie and concentration was measured using a NanoDrop spectrophotometer 
(ThermoScientific, Waltham, MA) (ε = 33,920 M-1 cm-1). Prior to SANS measurements, 
pure (protonated) MmIAP was buffer-exchanged using a 500 µL Amicon Ultra MWCO 
50K concentrator (Millipore) into gel filtration buffer containing 22% D2O (Acros 
Organic, Geel, Belgium).    
Fed-batch cultivation, expression of deuterated MmIAP (d-MmIAP), and cell 
lysis was carried out in the Bio-Deuteration Laboratory at Oak Ridge National Lab 
(ORNL). Prior to d-MmIAP production, E. coli Rosetta 2 cells were first adapted to D2O 
by transferring an individual colony of transformed cells from a Luria-Broth agar plate to 
0.5% (w/v) glycerol minimal medium in H2O and then subculturing into the same 
medium with an increasing D2O content (25, 50, 75 and 90%), 100 µg/mL carbenicillin, 
and 17 µg/mL chloramphenicol. Once the cells were growing in 90% D2O medium, a 400 
ml preculture was used to inoculate 3.6 L of fresh 90% D2O medium in a benchtop 
BioFlo 310 bioreactor system (Eppendorf, Hauppauge, NY) equipped with a 5.5 L 
working volume vessel. At the outset of the experiment, the temperature was maintained 
at 30 °C, aeration was maintained throughout at 4 L/min, and agitation was varied from 
200 – 800 rpm to maintain dissolved oxygen above a set point of 30% saturation. A 
solution of 10% (w/v) NaOH in 90% D2O was added on demand to maintain a pD >7.3. 
When the dissolved oxygen spike occurred upon depletion of the 0.5% (w/v) glycerol, a 
feeding of a solution consisting of 10% (w/v) glycerol and 0.2% MgSO4 in 90% D2O was 
initiated. After approximately 7 hours of feeding, the temperature set point was reduced 
to 18 °C and d-MmIAP expression was induced by adding 1 mM isopropyl-β-D-1-
thigalactopyranoside. Upon harvesting via centrifugation at 6,000 x g for 45 min, cell 
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paste containing d-MmIAP (~145 g wet cell weight) was suspended (0.1g/mL) in 50 mM 
Hepes (pH 7.5), 200 mM NaCl containing EDTA-Free SIGMAFAST™ Protease 
Inhibitor Cocktail Tablets (Sigma Aldrich, St. Louis, MO) and lysed at 15,000 psi via 
three passages through an EmulsiFlex-C3 homogenizer that was fitted with a chilled heat 
exchanger (Avestin, Ottawa, ON) and stationed in a 6 °C cold room. Following lysis, 
cellular debris was removed by centrifugation at 5,000 x g for 15 min four times. The 
supernatant (~1.8 L) was then subjected to ultracentrifugation at 162,000 x g for 30 min. 
The pelleted membrane fraction was washed by resuspension in a Dounce homogenizer 
and the membrane fraction was again isolated by ultracentrifugation as above. d-MmIAP 
-containing membranes (~22 g) were solubilized by gentle rocking for 0.5 hr at 4 °C in 
200 mL of a solution containing 50 mM Hepes (pH 7.5), 500 mM NaCl, 20 mM 
imidazole, and 4% (w/v) DDM. The membrane resuspension was subjected to 
ultracentrifugation as above to remove insoluble material. 
 The supernatant containing the solubilized membrane was purified using the 
protocol for MmIAP described above except for the following additional steps to 
maximize yield of purified enzyme. Namely, the flow through fractions from the first 
nickel affinity chromatography run were diluted in Buffer A lacking detergent to a final 
concentration of 2% DDM, and purified on the column again. A third round of nickel 
affinity chromatography was then performed on the flow through, from the second 
column, which was diluted with Buffer A lacking detergent to 1% DDM. Elution 
fractions from the three nickel affinity purification runs were pooled, concentrated to two 
~900 µL aliquots using a 15 mL Amicon Ultra MWCO 50K concentrator (Millipore), and 
each loaded onto a HiPrep 16/60 Sephacryl-S300 (GE Healthcare) pre-equilibrated as for 
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MmIAP above. Fractions containing purified d-MmIAP as judged by SDS-PAGE were 
pooled and a third Sephacryl-S300 column was used to further polish the sample. In a 
final step, purified d-MmIAP was loaded onto a Superose-12 10/300 GL (GE Healthcare) 
column equilibrated with 20 mM Hepes (pH 7.5), 250 mM NaCl, 48.5% D2O and 0.05% 
total DDM, of which 44% (w/v) is tail-deuterated d25-DDM (Anatrace) (Figure 4.1).  




Figure 4.1. d-MmIAP purification. Final size exclusion chromatogram (Superose-12 
10/300 GL column) for d-MmIAP equilibrated with 20 mM Hepes (pH 7.5), 250 mM 
NaCl, 48.5% D2O and 0.05% total DDM, of which 44% (w/v) is tail-deuterated d25-DDM 
(Anatrace). Inset: SDS-PAGE analysis of pooled fractions labeled A, B, C. Region 
labelled “B” was used in the SANS experiment. 
 
4.3.2 Small-Angle Neutron Scattering Data Collection 
SANS data were collected at the Bio-SANS beam line CG-3 of the High-Flux 
Isotope Reactor at ORNL using a single instrument configuration with 7-meter sample-
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to-detector distance. Data were collected at 12 ºC using 1mm quartz cells and neutron 
wavelength of 6 Å ±14%. The range of momentum transfer Q used was 0.007 < Q < 0.7 
Å-1 (Q = 4π·sin(θ)/λ, where 2θ is the scattering angle and λ is the neutron wavelength). 
Additional descriptions of the instrument and setup have been previously published (200-
202). The recorded scattering data were circularly averaged, and reduced to 1D scattering 
profiles using MantidPlot software (203). Calibration of the SANS data to an absolute 
scale was performed by measuring a porous silica standard with known intensity at zero 
angle (extrapolated from a Debye-Bueche plot). Blank buffers containing the same % 
D2O as the samples were similarly measured and subtracted from the sample scattering 
for background correction using a toolkit developed by Dr. Ken Littrell (ORNL) for 
IgorPro. Subsequent data analysis and modelling of scattering profiles were facilitated 
with the ATSAS 2.6.1 program suite (EMBL – Hamburg) (156). 
4.3.3 SANS Data Analysis and Modelling 
An initial estimation of the Rg and forward scattering intensity (I0) was performed 
using PRIMUS (204). Core-shell ellipsoid shape models were fit to the scattering data 
using SasView v4.1 (205). Comparisons of SANS data for d-MmIAP to structures of 
MmIAP and presenilin in the Protein Data Bank (PDB) were conducted with CRYSON 
(206). For the simulation conditions, a deuteration fraction of 0.75 was used for the 
protein chain with a D2O fraction in the solvent of 0.49 to mimic the experimental 
contrast conditions.  
 ATSAS software tools were used for further modelling and interpretation of the 
structural SANS information for d-MmIAP in solution with contrast-matched detergent. 
The first step of this process employed GNOM (207) to generate a pair-distance 
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distribution function P(r), which described the relative interatomic distances within the 
scattering particle. Scattering data over the range 0.0106 < Q < 0.585 Å-1 were used for 
the real space transformation and subsequent modelling, and provided a P(r) curve with a 
single peak and Dmax of 46 Å. The Rg from the real space transformation was 16.7 ± 0.2 
Å with an I0 of 0.610 ± 0.001 cm
-1. The GNOM output was used for ab initio molecular 
shape generation with DAMMIF and DAMMIN (208,209). The P(r) data were used as an 
input for fast DAMMIF modelling to create seventeen initial dummy atom models 
(DAMs). These initial DAMs were aligned and averaged using DAMAVER (210), and 
one outlier from the seventeen was discarded based on normalized spatial discrepancy 
(NSD) values as its NSD value exceeded 2 standard deviations from the cluster mean 
(cluster NSD: 0.708 ± 0.018, outlier NSD: 0.749). After averaging in DAMAVER, the 
‘damstart’ (fixed-core) model was used for refinement with DAMMIN, yielding a single 
refined SANS envelope. Superimpositions of the SANS envelope with crystal structures 
were performed using SUPCOMB (211), which minimizes NSD to find the best 
alignment of the two models. 
4.4 Results  
4.4.1 SANS Analysis of d-MmIAP 
SAXS measurements showed, as expected, strong scattering signal from DDM 
micelles that was similar with and without MmIAP, and initial attempts of SANS 
experiments using non-deuterated MmIAP, DDM, and D2O/H2O were unsuccessful in 
isolating a signal for MmIAP unperturbed by scattering contributions from the surfactant 
(Figure 4.2). Therefore, d-MmIAP was expressed and purified (Figure 4.1) immediately 
prior to data collection, using established methods yielding active enzyme (56). Based on 
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other studies (212), the average deuteration level under growth conditions is 70-75%. 
Scattering from the d-MmIAP protein-detergent complex produced a stronger signal 
overall as a result of the increased protein contrast relative to the solvent, but 
contributions from the detergent were still present in the net scattering profile. These 
results are observed in a comparison of the MmIAP-DDM complex versus d-MmIAP-
DDM in the same DDM contrast-matched conditions (Figure 4.3). 
 
 
Figure 4.2. Preliminary (A) SAXS and (B) SANS data collected for solutions of micelles 
(DDM – unfilled markers) and the protein-detergent complex (PDC – filled markers). 
Strong similarity was observed in scattering profile shapes between these two conditions 
at all measured contrasts. Core-shell ellipsoid model fits are shown by the solid lines, 





Figure 4.3. SANS contrast match point measurements for DDM micelles, MmIAP with 
DDM, d-MmIAP with DDM (22% D2O), and d-MmIAP with DDM / d25-DDM mixed 
micelles (48.5% D2O). Light blue data points reproduced from (213). 
 
To achieve true extinction of any scattering contribution from DDM, a more 
refined approach was required. The individual contrast match points of hydrophobic 
DDM alkyl tails and hydrophilic maltoside head groups are 2% and 48.5% D2O, 
respectively, which is very far from the overall contrast match point (CMP) of 22% D2O. 
This, together with the similar size of both moieties and their distinctive location in a 
micelle core and shell, produces significant residual scattering, even at 22% D2O (Figure 
4.3, yellow data points, reproduced from (213)). This problem can be resolved by raising 
the CMP of the DDM micelle core to 48.5% D2O to match the shell by precisely blending 
44% (w/v) tail-deuterated DDM (d25-DDM) with regular DDM (213). Under these 
complete matching conditions, scattering features from DDM micelles were rendered 
negligible (Figure 4.3), which is readily apparent by the absence of a secondary 
maximum in the SANS profile.  
92 
 
 The combination of deuterated protein and completely contrast-matched mixed 
micelles yielded an interpretable SANS profile for the enzyme without interference from 
buffer and detergent components (Figure 4.3 and Figure 4.4A). Guinier analysis was 
performed on the low-Q scattering data defined by an upper limit of Q*Rg < 1.3, and 
provided estimates of I0 and Rg (Figure 4.4B). The measured Rg (16.1 ± 0.5 Å), and a 
Kratky plot illustrating the folded nature of the scattering object (Figure 4.4C), suggests 
that MmIAP is most likely monomeric with a compact, globular shape in detergent 
solution (214). The forward scattering intensity determined from the Guinier fit was 0.60 
± 0.01 cm-1. An indirect Fourier transform of the scattering data provided a plot 
describing the pair-distance distribution P(r) of intramolecular distances within the 
particle, constrained by a maximum particle dimension of 46 Å (Figure 4.4D). Molecular 
weight was estimated from the DAMMIN model and by the method described by Rambo 
and Tainer (215) (see Figure 4.5 for details). A summary of the physical parameters 
extracted from the SANS data in comparison to similar values obtained from the final 
SANS envelope and the PDB model (4HYC, chain A) is presented in Table 4.1. The 
combination of these results from SANS suggest a monomeric MmIAP size and shape 





Figure 4.4. SANS data obtained for d-MmIAP with contrast-matched DDM / d25-DDM 
mixed micelles (48.5% D2O). (A) A plot of the scattered intensity versus Q, a function of 
the scattering angle, with GNOM fit shown in solid line; (B) Guinier plot of the low 
angle scattering data with a linear fit in the Guinier region shown in solid line; (C) A 
Kratky plot of the same scattering data demonstrating the compact, folded shape of the 
particle; and (D) A pair-distance distribution function P(r) obtained from GNOM 







Figure 4.5. Determination of protein molecular weight from the SAS invariant QR. Data 
are replotted first as a modified Kratky plot (Q*I(Q) vs Q), where flexible and non-
flexible proteins, and even unfolded proteins, should converge with zero intensity at high 
Q. This plot is then integrated to an upper limit defined by the scattering signal decay or 
plateau of integration (Qmax ≈ 0.25 was used here). The ratio of I0 to this integrated value 
determines the volume-of-correlation for the particle to be used in estimating the 




Table 4.1. Summary of physical parameters from the SANS data, reconstructed DAM, 
and a related PDB entry (4HYC:A). 
Radius of Gyration (Å) Dmax (Å) Volume (Å3) 





16.7 19.4 46.0 47.7 72.9 21,030 20,590 31,258 
 
 
4.4.2 Particle molecular volume estimates 
 The SANS data were placed on absolute intensity scale, and an independent 
estimation of particle size from the forward scattering intensity (I0) is therefore in 
principle possible. The sample molecular weight (MW) can be determined using the 
calibrated I0 value, sample concentration (c), and particle contrast (Δρ) according to the 
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following equation:  




where NA is Avogadro’s number, and v is the partial specific volume of the protein (216). 
However, as Tainer et al. (215) have pointed out, this approach is difficult, given the 
limits in accuracy of known particle concentration and other factors. SANS experiments 
also have the added challenge of accurately assessing the particle’s neutron contrast, 
particularly when the particle is a protein expressed in deuterated growth media.  
 An estimate of the protein contrast was made by inferring the level of deuterium 
incorporation at non-exchangeable positions in the protein from published empirical 
evidence. Previous studies suggest that a protein expressed in growth media containing 
~90% D2O yields a protein with 70-75% incorporation of deuterium at the non-
exchangeable positions of the protein (212). Particle concentration was estimated to be 
2.52 ± 0.38 mg·mL-1 by NanoDrop spectrophotometer (ThermoScientific) measurements 
of the absorbance at 280 nm using a calculated molar extinction coefficient of 33,920 M-1 
cm-1 from the IAP primary sequence. Although no absorbance in this region was 
observed for protein-free detergent micelle solutions, we cannot completely exclude the 
possibility that the suspension of membrane protein in detergent micelles interferes with 
this concentration estimate. From the apparent intensity of our gel electrophoresis data, 
we place an upper boundary of the concentration at 5 mg·mL-1.  This limit, in conjunction 
with the uncertainties in particle contrast, yields a total range of uncertainty in molecular 
weight that is too broad to identify the oligomeric state of MmIAP from I0 with any 
useful accuracy.  
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 Conversely, we obtained estimates for the particle volume from two intensity 
scale independent methods: The DAMMIN model yields a total excluded particle volume 
of 20,590 Å3 in fair agreement with the calculated volume of monomeric MmIAP 
(31,258 Å3 from PDB 4HYC, chain A, using VADAR v1.8, Univ. of Alberta, or 40,778 
Å3 from primary sequence using MULCh, University of Sydney). The concentration-
independent approach described by Rambo and Tainer to determine molecular weight 
was also employed (215), using the SAS invariant QR and the following relationship for 
proteins:  






where QR = Vc
2·Rg
-1, and Vc is the volume-of-correlation.  Additional details and plots 
used to determine the volume-of-correlation from the integrated area of Q*I(Q) are 
provided in Figure 4.5. This approach yields a molecular weight of 16.4 kDa, smaller 
than a single molecule of MmIAP. Both estimates support the conclusion that MmIAP in 
solution is a rather small scattering object, a result that is consistent with the hypothesis 
of MmIAP being monomeric rather than oligomeric. 
4.4.3 Comparison to Crystal Structure and ab initio Modelling  
SANS profiles were calculated from available structures for pertinent enzymes 
(chain A from MmIAP PDB codes 4HYC, 4HYD, 4HYG, and 4Y6K, and chain B, 
presenilin from -secretase PDB codes 5A63, 5FN2, 5FN3, 5FN4, and 5FN5). The four 
MmIAP crystal structures are ~3.3-3.9 Å resolution, represent three different space 
groups, different bound states (apo and inhibited), and are similar to each other with root 
mean square deviation (r.m.s.d.) of ~0.5-0.8 Å. The five presenilin structures solved by 
cryo-electron microscopy are 4.0-4.3 Å resolution, and represent four apo states, as well 
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as one that is bound to an inhibitor. Presenilin shares just 15% identity with MmIAP yet 
r.m.s.d.s for the two different structures are just ~2.5-3 Å. CRYSON fits to the 
experimental data from representative members of each PDB group are shown in Figure 
4.6A. The simulated scattering profiles for structural monomers are in relative agreement 
with the measured scattering profile of d-MmIAP in contrast-matched, mixed d25-DDM / 
DDM micelles (Figure 4.6). Each structure appears somewhat larger than that measured 
in solution, denoted by the decrease in scattered intensity from the plateau at lower values 
of Q for the simulated SANS data compared to the measured data, but are much closer to 
the data than a hypothetical d-MmIAP dimer and tetramer (Figure 4.6A). The average Rg 
from the structure (19.4 Å, Table 4.1) is also ~3.4 Å larger than the Rg determined from a 
Guinier fit to the SANS data (16.1 ± 0.5 Å).  
Ab initio modeling from d-MmIAP SANS data with contrast-matched detergent 
recapitulates the overall agreement with the available structures. A representative 
scattering profile from the remaining DAMMIF models demonstrates strong agreement 
with the experimental data (Figure 4.6A) and the SANS profile of the DAMMIN-refined 
envelope was indistinguishable from this representative trace.  The SANS envelope 
shown here has a protrusion that is consistent with the predicted position of the long helix 
6, which contains the C-terminal GxGD motif, and a well leading to the general vicinity 
of the catalytic aspartates (Figure 4.6B). We note however, that not all sixteen DAMs 
show exactly these features in the same location; thus, the fit shown here agrees with the 
SANS data but this envelope is not the only possible model at this level of detail. The 
poorest fit is for helix 4, half of which appears to protrude beyond the SANS envelope in 
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accordance with the larger Rg and Dmax values (Table 4.1) and calculated scattering 
intensity at low Q values.  
 
 
Figure 4.6. CRYSON results and comparison to SANS data. (A) Simulated SANS 
profiles from CRYSON for representative PDB entries related to intramembrane aspartyl 
proteases. Scattering from a MmIAP dimer and tetramer were also simulated using chains 
A and B from 4HYC, or chains A-D from 4HYC, respectively, demonstrating that higher 
order oligomers are not consistent with the observed scattering. (B) The ab initio model 
was also overlaid with chain A from 4HYC to provide a 3D structural comparison. 
 
4.5 Discussion 
Despite the increasing number of available membrane protein structures in the 
protein data bank determined by X-ray crystallography, nuclear magnetic resonance 
spectroscopy, and cryo-electron microscopy, the percentage remains very low compared 
to the total membrane-bound proteome, and determining the oligomerization state of such 
99 
 
proteins in solution remains a major challenge (217-219). Here we used SANS to 
determine the molecular envelope and oligomerization state of an IAP in solution. Our 
strategy had three major components: (1) deuterating MmIAP during cell growth to 
increase the SANS signal from the enzyme (2) utilizing 44% d25-DDM to match the 
CMP of the hydrophobic tail core with that of the head group of the DDM micelle and (3) 
contrast matching the overall DDM micelle with 48.5% D2O to leave only scattering 
from d-MmIAP.  
 The process of contrast matching to detect only the signal from the membrane 
protein is inherently challenging (220); micelle-micelle interaction or protein-protein 
interactions can corrupt low-Q data, and the residual signal from incompletely matched 
lipid head and tail components limit data interpretation to gross structural changes under 
defined experimental conditions. Typically, SANS studies of membrane proteins employ 
the average contrast match point for the solubilizing agent. For example Bu et al. (221) 
overall contrast-matched the small unilamellar vesicles to detect a change in the 
oligomeric state of SecA upon nucleotide binding, and Zimmer et al. (222) used the 
average contrast match for DDM of 22% D2O to detect differences between truncated 
and full-length potassium channel KcsA solubilized in DDM under different pH 
conditions. With our improved understanding of the detergent contributions to neutron 
scattering (213), reinspection of numerous SANS studies that utilize a similar strategy 
(150,222-226) suggests that the scattering profile exhibits contributions due to 
incompletely matched surfactant or lipid components. Thus, our recent efforts have been 
aimed at improving the contrast matching protocol by matching the hydrophobic tail of 
the detergent to its head group prior to contrast matching the overall micelle with D2O. 
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One prior study used an analogous strategy with sodium dodecyl sulfate (227), but the 
current study is the first such application to study a membrane enzyme solubilized in 
DDM, a more mild detergent with a larger headgroup (218). The theoretical basis for the 
approach with DDM was recently reported (213), and resulted in a strong interpretable 
signal free of contribution from the detergent.  
 The d-MmIAP ab initio model in solution is consistent with an approximately 
spherical monomeric protein, not a dimer or higher ordered species suggested in earlier 
biochemical experiments for SPP and other human IAP family members. Interestingly, 
the experimentally determined Rg (16.1 ± 0.5 Å) from SANS is somewhat smaller than 
the calculated Rg (19.4 Å) from a monomer chain of crystalline MmIAP, indicating a 
more compact structure is present in solution. This finding agrees with the observation 
that crystallized MmIAP was trapped in an inactive conformation, with the two aspartates 
too far apart for catalysis. Detergent identity and concentration are well known to affect 
crystallization properties (91,228). In the case of the MmIAP crystal structure, perhaps 
the limited proteolytic digestion of the enzyme or mutations introduced to enhance 
crystallizability (54), led to a less compact bundle of transmembrane helices. 
Alternatively, the dynamic detergent micelles present during crystallization might affect 
the lattice (229-231), as would be expected for an α-helical membrane protein with 
predominantly membrane immersed helices (232). Our sample for SANS was prepared 
using the same methods as for our enzymatic study where it is active for nearly a week 
after purification (56), suggesting our SANS envelope reflects that of an active enzyme in 
detergent solution, but whether the protein remains a monomer in the presence of 
substrate is an open question for further study. 
101 
 
5 Chapter 5: Future directions 
 
 
5.1 Introduction  
Robust, fast and high throughput FRET-based continuous assay was developed to 
study the kinetics of IAP. High resolution LC-MS/MS study was also developed to 
identify cleavage sites of substrates. Small-angle neutron scattering study of IAP yielded 
a solution structure of IAP free from detergent micelles signal. Techniques, that we 
developed, contribute to the better understanding of physiochemical properties governing 
IAP proteolysis. However, there are several major outstanding questions that remain to be 
answered: how does substrate enter active site, how does IAP discriminate natural 
substrate from non-substrate etc. Substrate repertoire will be extended to better 
understand the substrate specificity of IAP. In addition, how familial Alzheimer’s 
disease-linked mutations found on C100 substrate affect IAP proteolysis will be 
identified. Moreover, using cross-linking technique and SANS, interaction between 
substrate, enzyme and lipid environment will be elucidated  
5.2 Evaluate quantitatively the effects of FAD mutations within the C100 
substrate on IAP kinetics and cleavage preferences 
 In addition to heritable mutations in presenilin leading to Alzheimer’s disease, are 
mutations in amyloid precursor protein (www.alzforum.org/mutations). The FAD-linked 
mutations within the C100 substrate sequence (e.g. T43I, T43A, I45T) affect the catalytic 
efficiency of γ-secretase and increase the ratio of Aβ42/40, a poor prognosticator for 
Alzheimer disease pathogenesis (233). However, how these C100 substrate mutations 
influence the cleavage specificity of γ-secretase remains elusive.  
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 My thesis work demonstrated that our IAP ortholog cleaves at two consecutive γ-
sites, A42-T43-V44, similar to γ-secretase production of Aβ42-Aβ43. Thus, the 
methodology developed in this thesis could be applied to decode the effects of these 
mutations on kinetics and cleavage site preferences. Since the chemical preference 
towards Thr is removed in T43I and T43A mutants, I hypothesize these will not be 
cleaved by our IAP whereas with I45T, I hypothesize a new cleavage sites at V44-T45-V46. 
Of interest is whether the original γ-site cleavage or the site adjacent to T45 will be the 
predominant, tying into positional preferences for the IAP-substrate pair.   
5.3 Clarify sequence preferences for IAP cleavage by expanding the 
substrate repertoire tested using assays developed in this thesis 
 Among 90 substrates for γ-secretase and 30 substrates for SPP, some are not 
biological substrates and there is no consensus motif among substrates (5,59). The factors 
influencing the substrate recognition and specificity of IAP remain elusive. Results of 
this thesis demonstrate that the substrate specificity of IAP is influenced by chemical 
preference for Thr as well as positional preference. By screening additional biological 
substrates of presenilin and SPP, substrate and positional preferences of IAP will be 
better defined. The selected substrates (Table 5.1) include proteins that play essential role 
in a number of biological processes and are related to human diseases (5,59). To assess 
cleavage site preferences, fusion protein substrates analogous to MRS and MCS will be 
generated with the transmembrane segments in Table 5.1 and then subjected to IAP 
cleavage and LC-MS analysis. I hypothesize that IAP will cleave some substrates 
(preprolactin, HLA-A, hepatitis C virus, Swine Fever Virus and ErbB4) preferentially at 
a polar residue, Thr or Ser, analogous to MRS and MCS. Some substrates (Notch, p75, 
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Delta, Jagged) do not have these residues, however. Cysteine might play a surrogate role 
for threonine at the scissile bond, but these may instead be forming dimers (234). In this 
case, I hypothesize that positional preferences will guide the predominant cleavage site.  
 After cleavage sites are analyzed, FRET-based substrates will be synthesized 
where a fluorophore/quencher pair (e.g. EDANS/DABCYL) will be attached on the 
terminii of 10 amino acid peptide substrate containing the identified cut site. Kinetic 
parameters associated with each substrate cleavage by IAP will be measured and 
compared. Since a significant improvement in catalytic efficiency was observed upon 
using C100FRET compared to non-natural Ren390FRET substrate, we hypothesize there 
will be a higher catalytic efficiency with the natural substrates of presenilin and SPP even 
when paired with a microbial ortholog.  
 
Table 5.1. Selected substrates where proposed cut site is underlined 
Substrate Sequence 
Proposed chemical preference at cut site 
Preprolactin MDSKGSSQKGSRLLLLLVVSNLLLCQGVV 
HLA-A*0301 MAVMAPRTLLLLLSGALALTQTWA 
Hepatitis C virus PGCSFSIFLLALLSCLTVPASA 
Swine Fev. virus RKKLEKALLAWAVITILLYQPVAA 
ErbB4 TPLIAAGVIGGLFILVIVGLTFAVYVRRK 








5.4 Characterize the substrate-enzyme complex 
 The current available crystal and electron microscopy structures of IAPs are in an 
active conformation, providing little insight into how substrates enter into the hydrophilic 
active site from the hydrophobic lipid membrane. The predominant proposal for substrate 
entry involves TM6 containing the YD motif and TM9, containing the presenilin PAL 
motif. It is possible to characterize the substrate-enzyme interaction and conformational 
changes of substrate and enzyme that occur upon binding using SANS. The ability of the 
SANS method to mask one component by matching its scattering length density with the 
background highlights the key component of interest in a macromolecular complex. In 
our case, substrate and enzyme are two components whose conformational changes will 
be monitored while the other is made invisible by matching with the background. The 
detergent micelles will be rendered invisible with the help of tail-deuterated DDM and 
D2O as described in Chapter 4.  
 First, molecular envelope of IAP with and without substrate peptide will be 
compared to observe the conformation changes of IAP upon peptide binding. IAP will be 
deuterated to increase the contrast between the IAP and the background containing the 
SANS-invisible small substrate peptide. The final ab initio model of apo and substrate-
bound IAP, processed from initial neutron scattering data, will be compared to probe the 
structural changes of IAP that occur upon substrate binding. In order to trap IAP in a 
substrate-bound state, a catalytic inactive mutant (D162A/N, D220A/N), which has been 
found to be able to bind to substrate peptide yet fail to cleave the peptide (56), should be 
used. Alternatively, non-hydrolyzable substrate analogs could also be used with WT IAP 
in this experiment.  
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 Second, the molecular envelope of the substrate with and without IAP will be 
compared. In order to determine what orientation substrate takes to enter the active site of 
IAP, the fusion substrate, MCS (or other fusion protein substrate of interest) instead of 
the small peptide, will be used so that the substrate is visible. The SANS experiment will 
be carried out on the IAP/MCS complex in which both proteins are deuterated, providing 
the molecular envelope for the complex as one unit. Protonated IAP, which can be 
rendered invisible by matching with the background, will be used in complex with 
deuterated MRS to visualize only the substrate in the enzyme-bound state. The difference 
in size of MBP (~45 kDa) and SUMO (~12 kDa), that are flanking the desired substrate 
region on MRS substrate, will allow us to easily identify their position respective to IAP, 
thereby determining the orientation of substrate in the active site of IAP. It may also be 
possible to deduce the route of substrate entry on the IAP.  The IAP-bound state of the 
fusion substrates will be compared to the unbound fusion substrates evaluated by SAXS, 
using methods for MRS in Chapter 3, to probe evaluate changes of MRS upon binding 
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